id,population,cdscontext,genes,phenotype,activityscore,allelestatus,lookupkey,drugid,alerttext,version
4169762,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4169763,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169764,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169765,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169766,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169767,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169768,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169769,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169770,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170806,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:17128,['n/a'],1
4170895,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:26225,['n/a'],1
4169771,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169772,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169773,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169774,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169775,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169776,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169777,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169778,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169788,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169779,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169780,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169781,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169782,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169783,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2C19 genotype may be important for amitriptyline dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4169784,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169785,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169786,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169787,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169830,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4170820,H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:17128,['n/a'],1
4171366,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:7833,['n/a'],1
4169789,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169790,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169791,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169792,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169793,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169794,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169795,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169796,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169797,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169852,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['n/a'],1
4169798,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169799,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169800,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169801,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169802,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169803,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169804,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169805,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169806,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169807,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169808,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169809,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169810,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169811,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169812,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169813,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169814,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169815,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169816,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169817,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169818,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169819,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170254,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4169820,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169821,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169822,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169823,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169824,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169825,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169826,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169827,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169828,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169829,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169831,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169832,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169833,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169834,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information.'],1
4169835,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169836,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4169837,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4169838,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4169839,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4169840,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4169841,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171367,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:7833,['n/a'],1
4169842,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169843,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169844,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169845,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169846,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169847,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169848,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169849,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169850,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169851,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170896,general,No CDS,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:26225,['n/a'],1
4169853,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169854,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169855,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169856,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169857,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169858,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169859,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169860,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169861,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169918,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169862,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169863,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169864,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169865,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169866,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169867,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169868,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169869,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169870,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169930,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4170897,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:26225,['n/a'],1
4169871,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169872,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169873,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169874,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169875,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169876,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169877,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169878,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169879,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169931,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4169932,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4169880,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169881,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169882,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169883,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169884,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169885,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169886,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169887,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169888,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169954,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4171576,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:5489,['n/a'],1
4169889,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169890,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169891,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169892,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169893,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169894,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169895,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169896,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169897,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169898,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169899,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4169900,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169901,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169902,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169903,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169904,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169905,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169906,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169907,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169955,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169908,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169909,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169910,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169911,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169912,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169913,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169914,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169915,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169916,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169917,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171034,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['n/a'],1
4169919,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169920,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169921,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169922,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169923,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169924,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4169925,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4169926,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4169927,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4169928,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4169929,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4169933,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169934,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169935,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169936,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169937,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169938,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169939,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169940,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169941,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171577,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:5489,['n/a'],1
4169942,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169943,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4169944,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169945,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:704,['n/a'],1
4169946,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169947,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169948,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169949,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169950,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169951,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169952,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169953,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169956,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169957,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169958,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169959,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169960,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169961,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169962,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169963,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169964,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169965,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171035,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['n/a'],1
4169966,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If amitriptyline is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4169967,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169968,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:704,['n/a'],1
4169969,general,Pre-test,['UGT1A1'],{'UGT1A1': 'No Result'},{'UGT1A1': 'No Result'},{},{'UGT1A1': 'No Result'},RxNorm:343047,['UGT1A1 genetic status may be predictive of cosmetic jaundice with this medication. A UGT1A1 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4169970,general,No CDS,['UGT1A1'],{'UGT1A1': 'Normal Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Normal Metabolizer'},RxNorm:343047,['n/a'],1
4169971,general,No CDS,['UGT1A1'],{'UGT1A1': 'Intermediate Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Intermediate Metabolizer'},RxNorm:343047,['n/a'],1
4169972,general,Post-test,['UGT1A1'],{'UGT1A1': 'Poor Metabolizer'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Poor Metabolizer'},RxNorm:343047,['This patient is predicted to be a UGT1A1 poor metabolizer and may be at an increased risk of developing jaundice with atazanavir use. Consider an alternative agent particularly if jaundice would be of concern to the patient. Please consult a clinical pharmacist for more information.'],1
4169973,general,No CDS,['UGT1A1'],{'UGT1A1': 'Indeterminate'},{'UGT1A1': 'n/a'},{},{'UGT1A1': 'Indeterminate'},RxNorm:343047,['n/a'],1
4169974,general,Pre-test,['SLCO1B1'],{'SLCO1B1': 'No Result'},{'SLCO1B1': 'No Result'},{},{'SLCO1B1': 'No Result'},RxNorm:83367,['SLCO1B1 genetic status may be predictive of the risk of atorvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4169975,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Increased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Increased Function'},RxNorm:83367,['n/a'],1
4169976,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Normal Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Normal Function'},RxNorm:83367,['n/a'],1
4169977,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Decreased Function'},RxNorm:83367,"['This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4169978,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Possible Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Possible Decreased Function'},RxNorm:83367,"['This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4169979,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Poor Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Poor Function'},RxNorm:83367,"['This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing atorvastatin-induced myopathy. Prescribe ≤20mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider rosuvastatin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4169980,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Indeterminate'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Indeterminate'},RxNorm:83367,['n/a'],1
4169981,general,Pre-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': 'No *31:01 result on file', 'HLA-B': 'No *15:02 result on file'}","{'HLA-A': 'No *31:01 result on file', 'HLA-B': 'No *15:02 result on file'}",RxNorm:2002,['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. Neither a HLA-B*15:02 nor HLA-A*31:01 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4169991,general,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose. Please consult a clinical pharmacist for more information.']",1
4169982,general,Post-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 positive', 'HLA-B': 'No *15:02 result on file'}","{'HLA-A': '*31:01 positive', 'HLA-B': 'No *15:02 result on file'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-B*15:02 genotype does not appear to have been ordered for this patient. HLA-B*15:02 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4169983,general,Pre-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 negative', 'HLA-B': 'No *15:02 result on file'}","{'HLA-A': '*31:01 negative', 'HLA-B': 'No *15:02 result on file'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-A*31:01 negative. There is no reason to alter carbamazepine therapy based on the HLA-A*31:01 result. Because a HLA-B*15:02 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169984,general,Post-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': 'No *31:01 result on file', 'HLA-B': '*15:02 positive'}","{'HLA-A': 'No *31:01 result on file', 'HLA-B': '*15:02 positive'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for SJS/TEN is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. A HLA-A*31:01 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.']",1
4169985,general,Post-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 positive'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 positive'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 positive and may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information.']",1
4169986,general,Post-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 positive'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 positive'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 positive and HLA-A*31:01 negative. Based on the HLA-B*15:02 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information.']",1
4169987,general,Pre-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': 'No *31:01 result on file', 'HLA-B': '*15:02 negative'}","{'HLA-A': 'No *31:01 result on file', 'HLA-B': '*15:02 negative'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative. There is no reason to alter carbamazepine therapy based on the HLA-B*15:02 result. Because a HLA-A*31:01 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4169988,general,Post-test,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 negative'}","{'HLA-A': '*31:01 positive', 'HLA-B': '*15:02 negative'}",RxNorm:2002,"['HLA-B*15:02 and HLA-A*31:01 genetic status may be predictive of a severe cutaneous adverse reaction to carbamazepine. This patient is HLA-B*15:02 negative and HLA-A*31:01 positive. Based on the HLA-A*31:01 result, the patient may be at an increased risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and maculopapular exanthema (MPE). If the patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine. If the patient is carbamazepine-naïve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction. The latency period for cutaneous adverse drug reactions is short (< 8 weeks); therefore, if the patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine. Please consult a clinical pharmacist for more information.']",1
4169989,general,No CDS,"['HLA-B', 'HLA-A']",{},{},"{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 negative'}","{'HLA-A': '*31:01 negative', 'HLA-B': '*15:02 negative'}",RxNorm:2002,['n/a'],1
4169990,general,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:2556,['CYP2C19 genotype may be important for the use of citalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4169992,general,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and may be at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4169993,general,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:2556,['n/a'],1
4169994,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4169995,general,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4169996,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4169997,general,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:2556,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4169998,general,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:2556,['n/a'],1
4169999,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2C19 genotype may be important for clomipramine dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170000,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170001,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170002,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170003,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170004,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170005,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170006,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170007,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170008,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170009,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170010,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170011,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170061,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170062,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170012,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170013,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170014,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170015,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170016,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170017,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170018,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170019,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170020,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170238,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170021,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4170022,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170023,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170024,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170025,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170026,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170027,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170028,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170029,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170083,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170030,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170031,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170032,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170033,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170034,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170035,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170036,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170037,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170038,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170255,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170039,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170040,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170041,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170042,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170043,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170044,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170045,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170046,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170047,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170048,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171578,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:5489,['n/a'],1
4170049,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170050,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170051,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170052,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170053,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170054,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170055,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170056,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170057,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170058,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170059,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170060,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170063,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170064,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170065,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170066,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170067,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170068,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['n/a'],1
4170069,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170070,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170071,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170072,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170269,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4171579,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:5489,['n/a'],1
4170073,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170074,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170075,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170076,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170077,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170078,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170079,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170080,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170081,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170082,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170270,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170084,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170085,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170086,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170087,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information.'],1
4170088,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170089,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170090,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170091,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170092,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170093,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171036,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['n/a'],1
4170094,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170095,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170096,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170097,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170098,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170099,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170100,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170101,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170102,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170229,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170103,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170104,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170105,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170106,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170107,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170108,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170109,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170110,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170111,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171104,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:10324,['n/a'],1
4171105,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:10324,['n/a'],1
4170112,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170113,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170114,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170115,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170116,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170117,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170118,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170119,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170120,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170230,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170121,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170122,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170123,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170124,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170125,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170126,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170127,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170128,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170129,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170231,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170130,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170131,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170132,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170133,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170134,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170135,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170136,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170137,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170138,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170590,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2C19 genotype may be important for imipramine dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170139,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170140,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170141,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170142,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170143,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170144,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170145,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170146,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170147,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170148,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170232,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170149,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170150,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170151,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170152,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170153,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170154,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170155,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170156,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170157,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170233,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:3247,['n/a'],1
4170158,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170159,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170160,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170161,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170162,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170163,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170164,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170165,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170166,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170167,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170168,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170169,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170170,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170171,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170172,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170173,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170174,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170175,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170176,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170177,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,['n/a'],1
4170178,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170179,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170234,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:3247,['n/a'],1
4170235,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:3247,['n/a'],1
4170236,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:3247,['n/a'],1
4170180,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170181,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170182,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If clomipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170183,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170184,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170185,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170186,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170187,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170188,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170189,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170237,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:3247,['n/a'],1
4171106,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:10324,['n/a'],1
4171107,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:10324,['n/a'],1
4170190,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170191,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170192,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170193,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170194,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170195,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170196,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170197,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170198,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170199,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170200,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['n/a'],1
4170201,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170202,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171108,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:10324,['n/a'],1
4170203,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170204,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170205,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:2597,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If clomipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170206,general,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:32968,"[""The patient's CYP2C19 genotype may be important for choice of antiplatelet therapy. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170207,general,No CDS,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:32968,['n/a'],1
4170208,general,No CDS,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:32968,['n/a'],1
4170209,general,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:32968,['n/a'],1
4170210,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:32968,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information.']",1
4170211,general,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:32968,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Avoid standard dose clopidogrel (75 mg) if possible due to the risk of therapeutic failure in patients that had a recent acute coronary syndrome and/or a percutaneous coronary intervention, or a neurovascular indication for clopidogrel. Consider use of an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information.']",1
4170212,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:32968,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information.']",1
4170213,general,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:32968,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Avoid clopidogrel if possible due to the risk of therapeutic failure. Use an alternative antiplatelet agent at standard dose if no contraindication. Prasugrel is contraindicated in patients with a history of transient ischemic attack or stroke. Please consult a clinical pharmacist for more information.']",1
4170214,general,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:32968,['n/a'],1
4170215,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:27340,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4171109,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:10324,['n/a'],1
4171110,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:10324,['n/a'],1
4170216,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:27340,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170217,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:27340,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170218,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:27340,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170219,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:27340,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170220,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:27340,['n/a'],1
4170221,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:3247,['CYP2D6 genetic status may be important for desipramine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170222,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170223,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170224,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170225,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170226,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170227,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170228,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If desipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170821,general,Pre-test,['SLCO1B1'],{'SLCO1B1': 'No Result'},{'SLCO1B1': 'No Result'},{},{'SLCO1B1': 'No Result'},RxNorm:6472,['SLCO1B1 genetic status may be predictive of the risk of lovastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative drug or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170239,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170240,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170241,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170242,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:3247,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and may experience higher than expected plasma concentrations of desipramine resulting in an increased the probability of adverse reactions. Consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170243,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:3247,['n/a'],1
4170244,non-H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:816346,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170245,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170246,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:816346,['n/a'],1
4170247,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:816346,['n/a'],1
4170248,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170249,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170250,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170251,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170252,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:816346,['n/a'],1
4170253,H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:816346,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170822,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Increased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Increased Function'},RxNorm:6472,['n/a'],1
4170256,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170257,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170258,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170259,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170260,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:816346,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170261,H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:816346,['n/a'],1
4170262,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170263,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170264,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170265,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170266,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170267,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170268,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170823,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Normal Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Normal Function'},RxNorm:6472,['n/a'],1
4170271,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170272,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170273,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170274,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170275,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170276,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170277,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170278,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170279,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170280,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171111,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:10324,['n/a'],1
4171112,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:10324,['n/a'],1
4170281,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170282,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170283,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170284,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170285,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170286,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170287,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170288,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170289,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170290,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170291,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170292,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170293,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170323,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170294,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170295,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170296,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170297,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170298,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170299,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170300,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170301,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170302,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171113,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:10324,['n/a'],1
4170303,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170304,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170305,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170306,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,['n/a'],1
4170307,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170308,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170309,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170310,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170311,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170312,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171114,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:10324,['n/a'],1
4170313,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170314,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170315,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170316,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170317,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170318,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170319,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170320,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170321,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170322,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170324,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170325,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170326,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170327,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170328,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170329,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170330,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170331,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170332,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170333,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170334,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170335,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170336,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170337,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170338,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170339,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170340,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170341,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170342,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170591,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170343,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170344,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170345,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170346,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170347,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170348,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170349,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170350,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170351,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170352,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170353,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170354,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170355,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170356,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170357,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170358,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170359,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170360,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170361,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171115,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:10324,['n/a'],1
4171116,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:10324,['n/a'],1
4170362,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170363,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170364,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170365,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170366,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170367,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170368,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170369,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170370,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170381,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170371,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170372,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170373,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170374,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170375,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170376,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170377,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170378,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information.'],1
4170379,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170380,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170382,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170383,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170384,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170385,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170386,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170387,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170388,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170389,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170390,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170391,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170500,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'No Result'}","{'CYP2C9': '2.0', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 normal metabolizer. Based on CYP2C9 phenotype there is no reason to adjust the dose of fluvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170392,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170393,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170394,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170395,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170396,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170397,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170398,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['n/a'],1
4170399,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170400,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170401,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170433,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170402,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170403,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170404,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170405,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170406,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170407,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170408,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170409,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170410,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170411,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170412,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170413,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170475,general,No CDS,['CYP2B6'],{'CYP2B6': 'Indeterminate'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Indeterminate'},RxNorm:195085,['n/a'],1
4170970,general,Pre-test,['SLCO1B1'],{'SLCO1B1': 'No Result'},{'SLCO1B1': 'No Result'},{},{'SLCO1B1': 'No Result'},RxNorm:861634,['SLCO1B1 genetic status may be predictive of the risk of pitavastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170414,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170415,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170416,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170417,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170418,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170419,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170420,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170421,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,['n/a'],1
4170422,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170423,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170537,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 possible decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170424,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170425,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170426,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170427,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170428,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170429,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170430,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170431,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170432,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170434,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170435,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170436,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170437,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170438,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170439,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170440,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170441,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170442,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170443,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170538,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,['n/a'],1
4171901,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:39786,['n/a'],1
4170444,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170445,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170446,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170447,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170448,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170449,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170450,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170451,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170452,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170971,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Increased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Increased Function'},RxNorm:861634,['n/a'],1
4170453,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170454,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170455,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",RxNorm:3638,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4170456,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170457,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170458,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170459,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170460,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170461,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170462,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170463,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170464,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170465,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170466,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If doxepin is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170467,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2C19 genotype may be important for doxepin dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170468,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:3638,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170469,general,Pre-test,['CYP2B6'],{'CYP2B6': 'No Result'},{'CYP2B6': 'No Result'},{},{'CYP2B6': 'No Result'},RxNorm:195085,['CYP2B6 genetic status may be predictive of adverse events with efavirenz. A CYP2B6 genotype does not appear to have been ordered for this patient. A decreased dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170470,general,No CDS,['CYP2B6'],{'CYP2B6': 'Ultrarapid Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Ultrarapid Metabolizer'},RxNorm:195085,['n/a'],1
4170471,general,No CDS,['CYP2B6'],{'CYP2B6': 'Rapid Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Rapid Metabolizer'},RxNorm:195085,['n/a'],1
4170472,general,No CDS,['CYP2B6'],{'CYP2B6': 'Normal Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Normal Metabolizer'},RxNorm:195085,['n/a'],1
4170473,general,Post-test,['CYP2B6'],{'CYP2B6': 'Intermediate Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Intermediate Metabolizer'},RxNorm:195085,['This patient is predicted to be a CYP2B6 intermediate metabolizer and may be at an increased risk of adverse events due to higher plasma concentrations of efavirenz. Consider initiating efavirenz with a decreased dose of 400 mg/day. Please consult a clinical pharmacist for more information.'],1
4170474,general,Post-test,['CYP2B6'],{'CYP2B6': 'Poor Metabolizer'},{'CYP2B6': 'n/a'},{},{'CYP2B6': 'Poor Metabolizer'},RxNorm:195085,['This patient is predicted to be a CYP2B6 poor metabolizer and may be at an increased risk of adverse events due to higher plasma concentrations of efavirenz. Consider initiating efavirenz with a decreased dose of 200 or 400 mg/day. Please consult a clinical pharmacist for more information.'],1
4170476,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:3920,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170477,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:3920,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170478,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:3920,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170479,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:3920,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170480,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:3920,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170481,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:3920,['n/a'],1
4170482,general,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{},{},{'CYP2C19': 'No Result'},RxNorm:321988,['CYP2C19 genotype may be important for the use of escitalopram. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4170483,general,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170484,general,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and may be at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4170485,general,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:321988,['n/a'],1
4170486,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170487,general,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Initiate therapy with recommended starting dose, but consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170488,general,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170577,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '1.5'}",RxNorm:72236,['HLA-B*15:02 genotype may be important for fosphenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4170489,general,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:321988,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and is at risk for higher plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If escitalopram is clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170490,general,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{},{},{'CYP2C19': 'Indeterminate'},RxNorm:321988,['n/a'],1
4170491,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170492,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170493,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,['n/a'],1
4170494,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170495,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170496,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,['n/a'],1
4170497,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Indeterminate'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Indeterminate'}",RxNorm:41127,"['CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathydue to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient and SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170498,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'No Result'}","{'CYP2C9': '1.0', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170499,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'No Result'}","{'CYP2C9': '1.5', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of myopathy to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C9 intermediate metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >40mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170972,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Normal Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Normal Function'},RxNorm:861634,['n/a'],1
4171902,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:39786,['n/a'],1
4170501,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'No Result'}","{'CYP2C9': '0.0', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170502,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'No Result'}","{'CYP2C9': '0.5', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because a SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170503,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'No Result'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'No Result'}",RxNorm:41127,"['CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because an SLCO1B1 genotype does not appear to have been ordered for this patient and CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170504,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'No Result'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'No Result'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'No Result'}",RxNorm:41127,['CYP2C9 and SLCO1B1 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Neither a CYP2C9 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4170505,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information.']",1
4170506,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170507,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,['n/a'],1
4170508,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170509,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 decreased function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170510,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,['n/a'],1
4170511,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Decreased Function'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Decreased Function'}",RxNorm:41127,"['CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170512,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170513,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170514,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,['n/a'],1
4170515,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170516,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 normal function. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information.']",1
4170517,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,['n/a'],1
4170518,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Normal Function'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Normal Function'}",RxNorm:41127,"['CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170519,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. Thise patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170520,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170521,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 normal metabolizer and to have SLCO1B1 poor function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤40mg as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose > 40mg is needed for desired efficacy, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170522,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170523,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. The patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170524,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,"['This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg per day or an alternative statin or combination therapy. Because CYP2C9 phenotype could not be assigned based on genotyping performed, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171028,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,['n/a'],1
4170525,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Poor Function'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Poor Function'}",RxNorm:41127,"['This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient s tolerating 40mg per day or an alternative statin or combination therapy. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if CYP2C9 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170526,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170527,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >40mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170528,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,['n/a'],1
4170529,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170530,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': '0.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.5', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 increased. This patient may be at an increased risk of fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information.']",1
4170531,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Indeterminate', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'n/a', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,['n/a'],1
4170532,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Increased Function'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Increased Function'}",RxNorm:41127,"['CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170533,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': '1.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.0', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 possible decreased function. The patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If dose >20mg needed for desired efficacy, consider an alternative statin or combination therapy (i.e. fluvastatin plus non-statin guideline directed medical therapy). Please consult a clinical pharmacist for more information.']",1
4170534,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Intermediate Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': '1.5', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '1.5', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,"['This patient is predicted to be a CYP2C9 intermediate metabolizer and to have SLCO1B1 possible decreased function. Thise patient may be at an increased risk of a fluvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of fluvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170535,general,No CDS,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Normal Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': '2.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '2.0', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,['n/a'],1
4170536,general,Post-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'Poor Metabolizer', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': '0.0', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': '0.0', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,['This patient is predicted to be a CYP2C9 poor metabolizer and to have SLCO1B1 poor function. This patient is at an increased risk of a fluvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4171903,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:39786,['n/a'],1
4170539,general,Pre-test,"['CYP2C9', 'SLCO1B1']","{'CYP2C9': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}","{'CYP2C9': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'CYP2C9': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:41127,"['CYP2C9 genetic status may be predictive of the risk of fluvastatin-induced myopathy due to altered drug exposure. Because a CYP2C9 genotype does not appear to have been ordered for this patient, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170540,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:42355,['CYP2D6 genotype may be important for fluvoxamine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4170541,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:42355,['n/a'],1
4170542,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:42355,['n/a'],1
4170543,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:42355,['n/a'],1
4170544,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:42355,['n/a'],1
4170545,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:42355,['n/a'],1
4170546,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:42355,['n/a'],1
4170547,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:42355,['n/a'],1
4170548,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:42355,['n/a'],1
4170549,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:42355,['n/a'],1
4170550,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:42355,['n/a'],1
4170551,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:42355,['n/a'],1
4170552,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:42355,['n/a'],1
4170553,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:42355,['n/a'],1
4170554,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:42355,['n/a'],1
4170555,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:42355,['n/a'],1
4170556,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:42355,['n/a'],1
4170557,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:42355,['n/a'],1
4170558,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:42355,['n/a'],1
4170559,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:42355,['n/a'],1
4170560,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:42355,['n/a'],1
4170561,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:42355,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a 25-50% reduction in recommended starting dose and slower titration schedule or consider a clinicaly appropriate alternative not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170562,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:42355,['n/a'],1
4170563,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",RxNorm:72236,['n/a'],1
4170564,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",RxNorm:72236,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. Please consult a clinical pharmacist for more information']",1
4170565,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",RxNorm:72236,['n/a'],1
4171029,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,['n/a'],1
4170566,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",RxNorm:72236,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. Please consult a clinical pharmacist for more information.']",1
4170567,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",RxNorm:72236,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. Please consult a clinical pharmacist for more information.']",1
4170568,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",RxNorm:72236,['n/a'],1
4170569,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",RxNorm:72236,['CYP2C9 diplotype may be important for fosphenytoin dosing. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170570,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170571,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170572,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170573,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170574,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170575,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170576,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",RxNorm:72236,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to fosphenytoin. DO NOT prescribe fosphenytoin, fosfosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used fosphenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of fosphenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170578,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '1.0'}",RxNorm:72236,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to fosphenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information""]",1
4170579,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '2.0'}",RxNorm:72236,['HLA-B*15:02 genotype may be important for fosphenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4170580,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '0.5'}",RxNorm:72236,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to fosphenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.""]",1
4170581,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '0.0'}",RxNorm:72236,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to fosphenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing fosphenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.""]",1
4170582,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': 'n/a'}",RxNorm:72236,['HLA-B*15:02 genotype may be important for fosphenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4170583,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': 'No Result'}",RxNorm:72236,['A CYP2C9 and HLA-B*15:02 genotype does not appear to have been ordered for this patient. HLA-B and CYP2C9 genotype may be important for fosphenytoin dosing and use.Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170584,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:5095,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170585,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:5095,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170586,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:5095,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170587,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:5095,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170588,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:5095,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170589,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:5095,['n/a'],1
4170592,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170593,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170594,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170595,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170596,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170597,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170598,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170599,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170824,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Decreased Function'},RxNorm:6472,"['This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information.']",1
4170600,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170601,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170602,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170603,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170604,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170605,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170606,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170607,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170608,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171030,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,['n/a'],1
4170609,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170610,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170611,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170612,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4170613,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170614,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170615,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170616,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170617,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171031,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,['n/a'],1
4170618,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170619,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170620,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170621,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170622,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170623,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170624,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170625,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170626,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170627,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170628,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170629,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170630,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170631,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170632,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170633,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170634,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170635,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170636,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170637,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170638,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170639,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170640,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170641,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170642,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170643,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170644,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170645,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170646,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170647,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170648,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170649,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170650,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170651,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170652,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170653,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170654,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170655,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170656,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170657,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170658,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170659,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['n/a'],1
4170660,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171681,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:7454,['This patient has a result consistent with G6PD deficiency. Use nitrofurantoin with caution and monitor the patient for signs of hemolysis. Please consult a clinical pharmacist for more information.'],1
4170661,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170662,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170663,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170664,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170665,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170666,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170667,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170668,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170669,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170670,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170671,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170672,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170673,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170674,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170675,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170676,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4170677,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170678,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information.'],1
4170679,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170680,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170681,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170682,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170683,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170684,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170685,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170686,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170687,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170688,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170689,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170690,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170913,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170691,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170692,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170693,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170694,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170695,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170696,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170697,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170698,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170699,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170700,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170701,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170702,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170703,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170704,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170705,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170706,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4170707,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170708,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170825,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Possible Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Possible Decreased Function'},RxNorm:6472,"['This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If lovastatin therapy is warranted, limit dose to ≤20mg per day. Please consult a clinical pharmacist for more information.']",1
4170709,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170710,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170711,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170712,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170713,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170714,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170715,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170716,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170717,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170727,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170718,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170719,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170720,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170721,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170722,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170723,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170724,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170725,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170726,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170826,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Poor Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Poor Function'},RxNorm:6472,['This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing lovastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4170728,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170729,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170730,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170731,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170732,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170733,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170734,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170735,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170736,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170737,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170827,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Indeterminate'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Indeterminate'},RxNorm:6472,['n/a'],1
4170738,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170739,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170740,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170741,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170742,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170743,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170744,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170745,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170746,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170887,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:26225,['n/a'],1
4170888,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:26225,['n/a'],1
4170747,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170748,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170749,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170750,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170751,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170752,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170753,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170754,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170755,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170756,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170889,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:26225,['n/a'],1
4170757,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170758,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170759,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170760,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170761,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170762,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170763,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170764,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170765,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170766,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170767,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170768,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,['n/a'],1
4170890,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:26225,['n/a'],1
4170891,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:26225,['n/a'],1
4170769,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170770,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170771,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170772,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4170773,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If imipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170774,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170775,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170776,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170777,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170778,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170804,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170779,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170780,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170781,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170782,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170783,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170784,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170785,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170786,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170787,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170788,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170789,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170790,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170791,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['n/a'],1
4170805,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:17128,['n/a'],1
4170792,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170793,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170794,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170795,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170796,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:5691,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If imipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4170797,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:6026,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170798,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6026,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170799,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:6026,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170800,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6026,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170801,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:6026,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170802,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6026,['n/a'],1
4170803,non-H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:17128,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170807,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170808,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170809,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170810,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170811,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:17128,['n/a'],1
4170812,H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:17128,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170813,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170814,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170815,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170816,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170817,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170818,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170819,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:17128,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170828,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:6857,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170829,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6857,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4170830,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:6857,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170831,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6857,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170832,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:6857,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4170833,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:6857,['n/a'],1
4170834,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:7531,['CYP2D6 genetic status may be important for nortriptyline dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4170835,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170836,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170837,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170838,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170839,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170840,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170892,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:26225,['n/a'],1
4170841,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170842,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170843,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170844,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170845,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and may have lower than expected plasma concentrations resulting in an increased probability of pharmacotherapy failure. Consider alternative drug not metabolized by CYP2D6. If nortriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170846,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:7531,['n/a'],1
4170847,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:7531,['n/a'],1
4170848,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:7531,['n/a'],1
4170849,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:7531,['n/a'],1
4170850,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:7531,['n/a'],1
4170851,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of nortriptyline resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170852,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of nortriptyline resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170853,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of nortriptyline resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170854,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and may experience higher than expected plasma concentrations of nortriptyline resulting in an increased the probability of adverse reactions. Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170855,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:7531,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and may experience higher than expected plasma concentrations of nortriptyline resulting in an increased the probability of adverse reactions. Consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4170856,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:7531,['n/a'],1
4170857,non-H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:7646,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170858,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170859,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:7646,['n/a'],1
4170860,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:7646,['n/a'],1
4170861,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170862,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170863,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170864,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170865,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:7646,['n/a'],1
4170866,H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:7646,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170867,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170868,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170869,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170870,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170871,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170893,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:26225,['n/a'],1
4170894,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:26225,['n/a'],1
4170872,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170873,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:7646,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170874,H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:7646,['n/a'],1
4170875,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:26225,['CYP2D6 genetic status may be predictive of poor response to this medication. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4170876,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170877,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170878,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170879,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170880,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170881,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170882,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170883,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170884,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170885,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170886,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:26225,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of ondansetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4170898,general,Pre-test,['HLA-B'],{},{},{'HLA-B': 'No *15:02 result on file'},{'HLA-B': 'No *15:02 result on file'},RxNorm:32624,"['HLA-B*15:02 genetic status may be predictive of a severe cutaneous adverse reaction to oxcarbazepine, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). A HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4170899,general,Post-test,['HLA-B'],{},{},{'HLA-B': '*15:02 positive'},{'HLA-B': '*15:02 positive'},RxNorm:32624,"['HLA-B*15:02 genetic status may be predictive of a severe cutaneous adverse reaction to oxcarbazepine. This patient is HLA-B*15:02 positive and may be at an increased risk of oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). If the patient is oxcarbazepine-naive and alternative agents are available, do not use oxcarbazepine. The latency period for SJS/TEN is short (< 8 weeks); therefore, if the patient has previously used oxcarbazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine. Please consult a clinical pharmacist for more information.']",1
4170900,general,No CDS,['HLA-B'],{},{},{'HLA-B': '*15:02 negative'},{'HLA-B': '*15:02 negative'},RxNorm:32624,['n/a'],1
4170901,non-H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:40790,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170902,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170903,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:40790,['n/a'],1
4170904,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:40790,['n/a'],1
4170905,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170906,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170907,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170908,non-H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170909,non-H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:40790,['n/a'],1
4170910,H.pylori_erosive eso,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:40790,"[""CYP2C19 genotype may be important for this proton pump inhibitor's dosing. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.""]",1
4170911,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and is at risk for decreased plasma concentrations and therapeutic failure with standard dosing. Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170912,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer. The patient may be at risk for therapeutic failure at standard doses. Consider increasing the dose by 50-100%. Daily dose may be given in divided doses. Monitor for efficacy. Please consult a clinical pharmacist for more information.']",1
4170914,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170915,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170916,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170917,H.pylori_erosive eso,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:40790,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer. Initiate standard starting daily dose. If this proton pump inhibitor has been given for chronic therapy (>12 weeks) and after efficacy has been achieved, consider 50% reduction in daily dose to minimize the incidence of adverse events and monitor for continued efficacy. Please consult a clinical pharmacist for more information.']",1
4170918,H.pylori_erosive eso,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:40790,['n/a'],1
4170919,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:32937,['CYP2D6 genotype may be important for paroxetine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4170920,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170921,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170922,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170923,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170924,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170925,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170926,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170927,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170928,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170929,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170930,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4170931,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:32937,['n/a'],1
4170932,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:32937,['n/a'],1
4170933,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:32937,['n/a'],1
4170934,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:32937,['n/a'],1
4170935,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:32937,['n/a'],1
4170936,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a lower starting dose and slower titration schedule. Please consult a clinical pharmacist for more information.']",1
4170937,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a lower starting dose and slower titration schedule. Please consult a clinical pharmacist for more information.']",1
4170938,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a lower starting dose and slower titration schedule. Please consult a clinical pharmacist for more information.']",1
4170939,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 intermediate metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a lower starting dose and slower titration schedule. Please consult a clinical pharmacist for more information.']",1
4170940,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:32937,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4170941,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:32937,['n/a'],1
4170942,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.5'}",RxNorm:8183,['n/a'],1
4170943,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '1.0'}",RxNorm:8183,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. Please consult a clinical pharmacist for more information']",1
4170944,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '2.0'}",RxNorm:8183,['n/a'],1
4170945,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.5'}",RxNorm:8183,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. Please consult a clinical pharmacist for more information.']",1
4170946,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': '0.0'}",RxNorm:8183,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. Please consult a clinical pharmacist for more information.']",1
4170947,general,No CDS,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'n/a'}",RxNorm:8183,['n/a'],1
4170948,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': '*15:02 negative'},"{'HLA-B': '*15:02 negative', 'CYP2C9': 'No Result'}",RxNorm:8183,['CYP2C9 diplotype may be important for phenytoin dosing. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170949,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.5'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170950,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '1.0'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170951,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '2.0'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170952,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.5'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170953,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': '0.0'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170954,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'n/a'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170955,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': '*15:02 positive'},"{'HLA-B': '*15:02 positive', 'CYP2C9': 'No Result'}",RxNorm:8183,"['The HLA-B*15:02 allele has been detected in this patient. This allele is associated with high risk of cutaneous adverse drug reaction to phenytoin. DO NOT prescribe phenytoin, fosphenytoin, carbamazepine, or oxcarbazepine. Choose an alternate antiepileptic drug. If the patient has previously used phenytoin consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. For more information, please consult a clinical pharmacist.']",1
4170956,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '1.5'}",RxNorm:8183,['HLA-B*15:02 genotype may be important for phenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4171377,pediatrics,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:38400,['CYP2D6 genetic status may be predictive of poor response to this medication. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170957,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '1.0'}",RxNorm:8183,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to phenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information""]",1
4170958,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '2.0'}",RxNorm:8183,['HLA-B*15:02 genotype may be important for phenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4170959,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '0.5'}",RxNorm:8183,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to phenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.""]",1
4170960,general,Post-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': '0.0'}",RxNorm:8183,"[""CYP2C9 and HLA-B*15:02 genotype can affect a patient's response to phenytoin. Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer and is at increased risk for developing phenytoin-induced toxicities. For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.""]",1
4170961,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': 'n/a'}",RxNorm:8183,['HLA-B*15:02 genotype may be important for phenytoin adverse events. An HLA-B*15:02 genotype does not appear to have been ordered for this patient. Use of an alternative antiepileptic may be recommended. Please consult a clinical pharmacist for more information.'],1
4170962,general,Pre-test,"['CYP2C9', 'HLA-B']",{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{'HLA-B': 'No *15:02 result'},"{'HLA-B': 'No *15:02 result', 'CYP2C9': 'No Result'}",RxNorm:8183,['A CYP2C9 and HLA-B*15:02 genotype does not appear to have been ordered for this patient. HLA-B and CYP2C9 genotype may be important for phenytoin dosing and use.Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170963,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:8356,['CYP2C9 genotype may be important for piroxicam dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170964,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:8356,['n/a'],1
4170965,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:8356,['n/a'],1
4170966,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:8356,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of piroxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4170967,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:8356,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of piroxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4170968,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:8356,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of piroxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4170969,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:8356,['n/a'],1
4170973,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Decreased Function'},RxNorm:861634,"['This patient is predicted to have SLCO1B1 decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170974,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Possible Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Possible Decreased Function'},RxNorm:861634,"['This patient is predicted to have SLCO1B1 possible decreased function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤2mg as a starting dose and adjust doses of pitavastatin based on disease-spesific guidelines. If a dose >2mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170975,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Poor Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Poor Function'},RxNorm:861634,"['This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pitavastatin-induced myopathy. Prescribe ≤1mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. If a dose >1mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170976,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Indeterminate'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Indeterminate'},RxNorm:861634,['n/a'],1
4170977,general,Pre-test,['SLCO1B1'],{'SLCO1B1': 'No Result'},{'SLCO1B1': 'No Result'},{},{'SLCO1B1': 'No Result'},RxNorm:42463,['SLCO1B1 genetic status may be predictive of the risk of pravastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative statin or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4170978,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Increased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Increased Function'},RxNorm:42463,['n/a'],1
4170979,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Normal Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Normal Function'},RxNorm:42463,['n/a'],1
4170980,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Decreased Function'},RxNorm:42463,['n/a'],1
4170981,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Possible Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Possible Decreased Function'},RxNorm:42463,['n/a'],1
4170982,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Poor Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Poor Function'},RxNorm:42463,"['This patient is predicted to have SLCO1B1 poor function and may be at increased risk for developing pravastatin-induced myopathy. Prescribe ≤40mg per day as a starting dose and adjust doses of pravastatin based on disease-specific guidelines. If a dose >40mg is needed, consider a higher dose (>40mg) if patient is tolerating 40mg or an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170983,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Indeterminate'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Indeterminate'},RxNorm:42463,['n/a'],1
4170984,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Indeterminate'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Indeterminate'}",RxNorm:301542,"['This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170985,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Indeterminate'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Indeterminate'}",RxNorm:301542,"['This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170986,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Indeterminate'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Indeterminate'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Because SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170987,general,Pre-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Indeterminate'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Indeterminate'}",RxNorm:301542,"['ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Because an ABCG2 genotype does not appear to have been ordered for this patient and SLCO1B1 phenotype could not be assigned based on genotyping performed, it is not known if these results would influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171032,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,['CYP2B6 genotype may be important for the use of sertraline and does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4170988,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'No Result'}","{'ABCG2': 'n/a', 'SLCO1B1': 'No Result'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'No Result'}",RxNorm:301542,"['This patient is predicted to have ABCG2 decreased function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170989,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'No Result'}","{'ABCG2': 'n/a', 'SLCO1B1': 'No Result'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'No Result'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170990,general,Pre-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'No Result'}","{'ABCG2': 'n/a', 'SLCO1B1': 'No Result'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'No Result'}",RxNorm:301542,"['This patient is predicted to have ABCG2 normal function. Based on ABCG2 phenotype there is no reason to adjust the dose of rosuvastatin. Because an SLCO1B1 genotype does not appear to have been ordered for this patient, it is not known if SLCO1B1 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170991,general,Pre-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'No Result'}","{'ABCG2': 'No Result', 'SLCO1B1': 'No Result'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'No Result'}",RxNorm:301542,['ABCG2 and SLCO1B1 genetic status may be predictive of the risk of rosuvastatin-induced myopathy due to altered drug exposure. Neither a ABCG2 nor SLCO1B1 genotype appears to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4170992,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Decreased Function'}",RxNorm:301542,['n/a'],1
4170993,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Decreased Function'}",RxNorm:301542,['n/a'],1
4170994,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Decreased Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and SLCO1B1 decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170995,general,Pre-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Decreased Function'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Decreased Function'}",RxNorm:301542,"['This patient is predicted to have SLCO1B1 decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4170996,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Normal Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Normal Function'}",RxNorm:301542,['n/a'],1
4170997,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Normal Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Normal Function'}",RxNorm:301542,['n/a'],1
4170998,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Normal Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Normal Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and SLCO1B1 normal function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4170999,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Normal Function'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Normal Function'}",RxNorm:301542,"['This patient is predicted to have SLCO1B1 normal function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171000,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Poor Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Poor Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 decreased function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information.']",1
4171033,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['n/a'],1
4171001,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Poor Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Poor Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 normal function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >20mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information.']",1
4171002,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Poor Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Poor Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and SLCO1B1 poor function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider combination therapy. Please consult a clinical pharmacist for more information.']",1
4171003,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Poor Function'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Poor Function'}",RxNorm:301542,"['This patient is predicted to have SLCO1B1 poor function and may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose > 20mg is needed for desired efficacy, consider combination therapy. Because an ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171004,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Possible Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:301542,['n/a'],1
4171005,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Possible Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:301542,['n/a'],1
4171006,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Possible Decreased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and SLCO1B1 possible decreased function. This patient may be at an increased risk of a rosuvastatin-induced myopathy. Prescribe ≤10mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. If a dose >10mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4171007,general,Pre-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Possible Decreased Function'}",RxNorm:301542,"['This patient is predicted to have SLCO1B1 possible decreased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171008,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Increased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Decreased Function', 'SLCO1B1': 'Increased Function'}",RxNorm:301542,['n/a'],1
4171009,general,No CDS,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Normal Function', 'SLCO1B1': 'Increased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Normal Function', 'SLCO1B1': 'Increased Function'}",RxNorm:301542,['n/a'],1
4171010,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'Poor Function', 'SLCO1B1': 'Increased Function'}","{'ABCG2': 'n/a', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'Poor Function', 'SLCO1B1': 'Increased Function'}",RxNorm:301542,"['This patient is predicted to have ABCG2 poor function and SLCO1B1 increased function. This patient may be at an increased risk of rosuvastatin-induced myopathy. Prescribe ≤20mg per day as a starting dose and adjust doses of rosuvastatin based on disease-specific guidelines. If a dose >20mg is needed for desired efficacy, consider an alternative statin or combination therapy. Please consult a clinical pharmacist for more information.']",1
4171011,general,Post-test,"['SLCO1B1', 'ABCG2']","{'ABCG2': 'No Result', 'SLCO1B1': 'Increased Function'}","{'ABCG2': 'No Result', 'SLCO1B1': 'n/a'}",{},"{'ABCG2': 'No Result', 'SLCO1B1': 'Increased Function'}",RxNorm:301542,"['This patient is predicted to have SLCO1B1 increased function. Based on SLCO1B1 phenotype there is no reason to adjust the dose of rosuvastatin. Because a ABCG2 genotype does not appear to have been ordered for this patient, it is not known if ABCG2 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171012,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}",RxNorm:36437,['CYP2C19 genotype may be important for the use of sertraline. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171013,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'No Result'}",RxNorm:36437,['CYP2C19 genotype may be important for the use of sertraline. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171014,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}",RxNorm:36437,['CYP2C19 genotype may be important for the use of sertraline. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171015,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Because a CYP2C19 genotype does not appear to have been ordered for this patient, it is not known if CYP2C19 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171016,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6. Because a CYP2C19 genotype does not appear to have been ordered for this patient, it is not known if CYP2C19 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171017,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2B6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'No Result'}",RxNorm:36437,['CYP2C19 genotype may be important for the use of sertraline. A CYP2C19 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171018,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2B6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:36437,['CYP2C19 and CYP2B6 genotypes may be important for the use of sertraline and do not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171019,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and a CYP2B6 ultrarapid metabolizer and may be at risk for lower plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171020,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer and a CYP2B6 rapid metabolizer and may be at risk for lower plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171021,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,['n/a'],1
4171022,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,['n/a'],1
4171023,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,['n/a'],1
4171024,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,['n/a'],1
4171025,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:36437,['CYP2B6 genotype may be important for the use of sertraline and does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171026,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and a CYP2B6 ultrarapid metabolizer and may be at risk for lower plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171027,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer and a CYP2B6 rapid metabolizer and may be at risk for lower plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171037,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 normal metabolizer and a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171038,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['n/a'],1
4171039,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:36437,['CYP2B6 genotype may be important for the use of sertraline and does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171040,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,['n/a'],1
4171041,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,['n/a'],1
4171042,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer and a CYP2B6 normal metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171043,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer and a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171044,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer and a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171045,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely intermediate metabolizer may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171046,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 intermediate metabolizer and may be at risk for higer plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Because a CYP2B6 genotype does not appear to have been ordered for this patient, it is not known if CYP2B6 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.Please consult a clinical pharmacist for more information.']",1
4171047,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,['n/a'],1
4171048,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,['n/a'],1
4171049,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and a CYP2B6 normal metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171368,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:7833,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171050,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171051,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171052,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171053,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 intermediate metabolizer and may be at risk for higer plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Because a CYP2B6 genotype does not appear to have been ordered for this patient, it is not known if CYP2B6 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.Please consult a clinical pharmacist for more information.']",1
4171054,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 ultrarapid metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171055,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 rapid metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171056,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 normal metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171057,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171058,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171059,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171369,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:7833,['n/a'],1
4171370,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:7833,['n/a'],1
4171060,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171061,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and a CYP2B6 ultrarapid metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171062,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 likely poor metabolizer and a CYP2B6 rapid metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171063,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and a CYP2B6 normal metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171064,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171065,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and a CYP2B6 poor metabolizer and may be at risk for higher plasma concentrations with standard dosing. Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171066,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Please consult a clinical pharmacist for more information.']",1
4171067,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer and may be at risk for higer plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Because a CYP2B6 genotype does not appear to have been ordered for this patient, it is not known if CYP2B6 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.']",1
4171068,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,['n/a'],1
4171069,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Rapid Metabolizer', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,['n/a'],1
4171070,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,['n/a'],1
4171071,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2B6 intermediate metabolizer and may be at risk for higher plasma concentrations with standard dosing. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Please consult a clinical pharmacist for more information.']",1
4171072,general,Post-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer may be at risk for higher plasma concentrations with standard dosing. Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6. Please consult a clinical pharmacist for more information.']",1
4171073,general,No CDS,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,['n/a'],1
4171074,general,Pre-test,"['CYP2B6', 'CYP2C19']","{'CYP2B6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2B6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2B6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:36437,['CYP2B6 genotype may be important for the use of sertraline and does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171075,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:36453,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4171076,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:36453,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4171077,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:36453,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171078,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:36453,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171079,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:36453,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171080,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:36453,['n/a'],1
4171081,general,Pre-test,['SLCO1B1'],{'SLCO1B1': 'No Result'},{'SLCO1B1': 'No Result'},{},{'SLCO1B1': 'No Result'},RxNorm:36567,['SLCO1B1 genetic status may be predictive of the risk of simvastatin-induced myopathy due to altered drug exposure. An SLCO1B1 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4171082,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Increased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Increased Function'},RxNorm:36567,['n/a'],1
4171083,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Normal Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Normal Function'},RxNorm:36567,['n/a'],1
4171084,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Decreased Function'},RxNorm:36567,"['This patient is predicted to have SLCO1B1 decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information.']",1
4171085,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Possible Decreased Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Possible Decreased Function'},RxNorm:36567,"['This patient is predicted to have SLCO1B1 possible decreased function and is at increased risk for developing simvastatin-induced myopathy. Prescribe an alternative statin depending on the desired potency. If simvastatin therapy is warranted, limit dose to <20mg per day. Please consult a clinical pharmacist for more information.']",1
4171086,general,Post-test,['SLCO1B1'],{'SLCO1B1': 'Poor Function'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Poor Function'},RxNorm:36567,['This patient is predicted to have SLCO1B1 poor function and is at increased risk for developing simvastatin-inducedmyopathy. Prescribe an alternative statin depending on the desired potency. Please consult a clinical pharmacist for more information.'],1
4171087,general,No CDS,['SLCO1B1'],{'SLCO1B1': 'Indeterminate'},{'SLCO1B1': 'n/a'},{},{'SLCO1B1': 'Indeterminate'},RxNorm:36567,['n/a'],1
4171371,aspirin <1g,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:1191,['n/a'],1
4171088,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Malignant Hyperthermia Susceptibility'}",RxNorm:10154,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4171089,general,Post-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Malignant Hyperthermia Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:10154,"['Based on genotype, this patient is predicted to be malignant hyperthermia susceptible. Halogenated volatile anesthetics or depolarizing muscle relaxants are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available, effective, and safe in patients with MHS. Please consult an anesthesiologist or clinical pharmacist for more information.']",1
4171090,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}","{'RYR1': 'n/a', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'No Result'}",RxNorm:10154,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171091,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'No Result', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:10154,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171092,general,Pre-test,"['RYR1', 'CACNA1S']","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}","{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",{},"{'RYR1': 'No Result', 'CACNA1S': 'No Result'}",RxNorm:10154,['Malignant Hyperthermia Susceptibility is an inherited trait linked to changes within the RYR1 and CACNA1S genes. Genetic testing can help to guide anesthetic agent use.'],1
4171093,general,No CDS,"['RYR1', 'CACNA1S']","{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}","{'RYR1': 'n/a', 'CACNA1S': 'n/a'}",{},"{'RYR1': 'Uncertain Susceptibility', 'CACNA1S': 'Uncertain Susceptibility'}",RxNorm:10154,['n/a'],1
4171094,general,Pre-test,['CYP3A5'],{'CYP3A5': 'No Result'},{'CYP3A5': 'No Result'},{},{'CYP3A5': 'No Result'},RxNorm:42316,['CYP3A5 results may be important for tacrolimus dosing. A CYP3A5 genotype does not appear to have been ordered for this patient. Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171095,general,Post-test,['CYP3A5'],{'CYP3A5': 'Normal Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Normal Metabolizer'},RxNorm:42316,"['Based on the genotype result, this patient is predicted to have lower tacrolimus serum drug levels if initiated on a standard tacrolimus starting dose. Consider increasing the starting dose to 1.5 times to 2 times the standard dose. Total starting dose should not exceed 0.3mg/kg/day. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Use therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171096,general,Post-test,['CYP3A5'],{'CYP3A5': 'Intermediate Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Intermediate Metabolizer'},RxNorm:42316,"['Based on the genotype result, this patient is predicted to have lower tacrolimus serum drug levels if initiated on a standard tacrolimus starting dose. Consider increasing the starting dose to 1.5 times to 2 times the standard dose. Total starting dose should not exceed 0.3mg/kg/day. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Use therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171097,general,Post-test,['CYP3A5'],{'CYP3A5': 'Possible Intermediate Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Possible Intermediate Metabolizer'},RxNorm:42316,"['Based on the genotype result, this patient is predicted to have lower tacrolimus serum drug levels if initiated on a standard tacrolimus starting dose. Consider increasing the starting dose to 1.5 times to 2 times the standard dose. Total starting dose should not exceed 0.3mg/kg/day. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Use therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171098,general,No CDS,['CYP3A5'],{'CYP3A5': 'Poor Metabolizer'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Poor Metabolizer'},RxNorm:42316,['n/a'],1
4171099,general,No CDS,['CYP3A5'],{'CYP3A5': 'Indeterminate'},{'CYP3A5': 'n/a'},{},{'CYP3A5': 'Indeterminate'},RxNorm:42316,['n/a'],1
4171100,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:10324,['CYP2D6 genetic status may be predictive of poor response to this medication. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4171101,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:10324,['n/a'],1
4171102,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:10324,['n/a'],1
4171103,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:10324,['n/a'],1
4171117,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:10324,"['This patient is predicted to have lower than normal CYP2D6 activity and may be at an increased risk of a poor tamoxifen response due to low endoxifen (active component of tamoxifen) concentrations. Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 inhibitors. Please consult a clinical pharmacist for more information.']",1
4171118,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:10324,"['This patient is predicted to have lower than normal CYP2D6 activity and may be at an increased risk of a poor tamoxifen response due to low endoxifen (active component of tamoxifen) concentrations. Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 inhibitors. Please consult a clinical pharmacist for more information.']",1
4171119,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:10324,"['This patient is predicted to have lower than normal CYP2D6 activity and may be at an increased risk of a poor tamoxifen response due to low endoxifen (active component of tamoxifen) concentrations. Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 inhibitors. Please consult a clinical pharmacist for more information.']",1
4171120,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:10324,"['This patient is predicted to have lower than normal CYP2D6 activity and may be at an increased risk of a poor tamoxifen response due to low endoxifen (active component of tamoxifen) concentrations. Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 inhibitors. Please consult a clinical pharmacist for more information.']",1
4171121,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:10324,"['This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a poor tamoxifen response due to low endoxifen (active component of tamoxifen) concentrations. Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations in CYP2D6 poor metabolizers. Please consult a clinical pharmacist for more information.']",1
4171122,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:10324,['n/a'],1
4171123,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:37790,['CYP2C9 genotype may be important for Tenoxicam dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171124,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:37790,['n/a'],1
4171125,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:37790,['n/a'],1
4171126,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:37790,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of Tenoxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171127,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:37790,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of Tenoxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171128,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:37790,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of Tenoxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171129,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:37790,['n/a'],1
4171130,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'No Result'}","{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2C19 genotype may be important for trimipramine dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171131,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}","{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. Neither a CYP2D6 nor CYP2C19 genotype appears to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171132,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171133,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171134,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171135,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171136,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171137,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171138,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171139,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171140,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171141,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171142,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171143,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171144,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171145,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171146,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171147,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Because a CYP2C19 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171148,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171372,aspirin <1g,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:1191,['n/a'],1
4171373,aspirin <1g,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:1191,['n/a'],1
4171149,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171150,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171151,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'No Result'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171152,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'No Result'}","{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'No Result'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. A CYP2C19 genotype does not appear to have been ordered for this patient. CYP2C19 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.']",1
4171153,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171154,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171155,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171156,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171157,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171158,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171159,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171160,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171161,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171162,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171163,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171164,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171165,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171166,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171167,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171168,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171169,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171170,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a likely CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171171,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171172,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171173,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171174,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171175,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171176,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a likely CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171177,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171178,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171179,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171180,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171181,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171182,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171183,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171184,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171185,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171186,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171187,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171188,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a likely CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171189,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171190,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171191,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171192,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171193,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171194,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171195,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171196,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171197,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a likely CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171198,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Likely Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Likely Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a likely CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171199,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['n/a'],1
4171200,general,Pre-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171201,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171202,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171203,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171204,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171205,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171206,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171207,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171208,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171209,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171210,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171211,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171212,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4171213,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4171214,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4171215,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4171216,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2D6 result. Please consult a clinical pharmacist for more information.'],1
4171217,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171218,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.Please consult a clinical pharmacist for more information.'],1
4171219,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171220,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171221,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Indeterminate'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Indeterminate'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171222,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171223,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 ultarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171224,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171225,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171226,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171227,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171228,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171229,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171230,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171374,aspirin <1g,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:1191,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171231,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171232,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171233,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171234,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171235,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171236,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171237,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171238,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171239,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 ultrarapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171375,aspirin <1g,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:1191,['n/a'],1
4171376,aspirin <1g,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:1191,['n/a'],1
4171240,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171241,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171242,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171243,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 ultrarapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171244,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Ultrarapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Ultrarapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 ultrarapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171245,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171246,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. A CYP2D6 genotype does not appear to have been ordered for this patient. CYP2D6 genetic status may be important for alternative drugs. Please consult a clinical pharmacist for more information.'],1
4171247,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171248,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171362,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:641,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171249,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171250,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171251,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171252,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171253,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171254,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171255,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171256,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171257,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 rapid metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171267,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 rapid metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171258,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171259,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171260,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171261,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171262,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and CYP2C19 rapid metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171263,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171264,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171265,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171266,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Rapid Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Rapid Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 rapid metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171358,general,Pre-test,['HLA-B'],{},{},{'HLA-B': 'No *58:01 result on file'},{'HLA-B': 'No *58:01 result on file'},RxNorm:519,"['An HLA-B*58:01 genotype test does not appear to have been ordered for this patient. Patients who carry this allele are at increased risk of serious dermatologic reactions with the use of allopurinol, including Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Please consult a clinical pharmacist for more information.']",1
4171268,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171269,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 poor metabolizer and may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171270,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171271,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171272,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171273,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171274,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171275,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171276,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171277,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171359,general,No CDS,['HLA-B'],{},{},{'HLA-B': '*58:01 negative'},{'HLA-B': '*58:01 negative'},RxNorm:519,['n/a'],1
4171278,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171279,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171280,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 poor metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171281,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171282,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171283,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171284,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171285,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 normal metabolizer and a CYP2C19 poor metabolizer. Based on the CYP2C19 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2C19. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171286,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171360,general,Post-test,['HLA-B'],{},{},{'HLA-B': '*58:01 positive'},{'HLA-B': '*58:01 positive'},RxNorm:519,"['The patient carries the HLA-B*58:01 allele, which indicates that the patient is at risk of developing a serious dermatologic reaction, including Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome. Allopurinol is contraindicated. Please consult a clinical pharmacist for more information.']",1
4171287,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171288,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171289,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 poor metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171290,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Poor Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Poor Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171291,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 normal metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171292,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171293,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171294,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171295,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171296,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171363,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:641,['n/a'],1
4171297,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171298,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171299,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171300,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171301,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171302,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171303,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171304,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171305,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171306,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171307,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171308,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,['n/a'],1
4171364,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:641,['n/a'],1
4171309,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4171310,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4171311,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4171312,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, the patient may be at an increased risk of a sub-optimal response. Consider a 25% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments.']",1
4171313,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Normal Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Normal Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 normal metabolizer. Based on the CYP2D6 result, this patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug not metabolized by CYP2D6. If trimipramine is warranted, consider a 50% reduction of recommended starting dose and utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.']",1
4171314,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'No Result', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'No Result', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,"['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2C19 intermediate metabolizer. There is no reason to selectively adjust the dose of this medication based on the CYP2C19 result. Because a CYP2D6 genotype does not appear to have been ordered for this patient, use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.']",1
4171315,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Indeterminate', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': 'n/a', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': 'n/a', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171316,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥6.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥6.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171317,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥5.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥5.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171318,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171361,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:641,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171319,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171320,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171321,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171322,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '≥3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '≥3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171323,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '4.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '4.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171324,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171325,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '3.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '3.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171326,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Ultrarapid Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 ultrarapid metabolizer and a CYP2C19 intermediate metabolizer. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171327,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171328,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '2.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '2.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171329,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171330,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171331,general,No CDS,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Normal Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['n/a'],1
4171365,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:7833,['n/a'],1
4171332,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '1.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '1.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171333,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.75', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.75', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171334,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.5', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.5', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171335,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Intermediate Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.25', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.25', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 intermediate metabolizer and a CYP2C19 intermediate metabolizer. The patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171336,general,Post-test,"['CYP2D6', 'CYP2C19']","{'CYP2D6': 'Poor Metabolizer', 'CYP2C19': 'Intermediate Metabolizer'}","{'CYP2D6': '0.0', 'CYP2C19': 'n/a'}",{},"{'CYP2D6': '0.0', 'CYP2C19': 'Intermediate Metabolizer'}",RxNorm:10834,['CYP2D6 and CYP2C19 genetic status may be predictive of an adverse reaction or poor response to this medication due to altered drug metabolism. This patient is predicted to be a CYP2D6 poor metabolizer and a CYP2C19 intermediate metabolizer. This patient may be at an increased risk of a sub-optimal response. Consider selecting an alternative drug. If trimipramine is warranted utilize therapeutic drug monitoring to guide dose adjustments. Please consult a clinical pharmacist for more information.'],1
4171337,pediatrics,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:121243,['CYP2C19 genotype may be important for voriconazole dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171338,pediatrics,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer, and the probability of attainment of therapeutic concentrations is small. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Please consult a clinical pharmacist for more information.']",1
4171339,pediatrics,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer, and the probability of attainment of therapeutic concentrations is variable. Initiate therapy with recommended standard of care dosing. Meticulous therapeutic drug monitoring to titrate dose to therapeutic trough concentrations is critical due to large variability in trough concentrations in rapid metabolizers. Please consult a clinical pharmacist for more information.']",1
4171340,pediatrics,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:121243,['n/a'],1
4171341,pediatrics,No CDS,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:121243,['n/a'],1
4171342,pediatrics,No CDS,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:121243,['n/a'],1
4171343,pediatrics,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer, and higher than normal trough concentrations of voriconazole are likely with normal starting dosages and may increase the probability of adverse reactions. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Where voriconazole is strongly indicated for treatment of an invasive mycosis, administration of a lower dosage with meticulous therapeutic drug monitoring may be feasible. Please consult a clinical pharmacist for more information.']",1
4171344,pediatrics,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer, and higher than normal trough concentrations of voriconazole are likely with normal starting dosages and may increase the probability of adverse reactions. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Where voriconazole is strongly indicated for treatment of an invasive mycosis, administration of a lower dosage with meticulous therapeutic drug monitoring may be feasible. Please consult a clinical pharmacist for more information.']",1
4171345,pediatrics,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:121243,['n/a'],1
4171346,adults,Pre-test,['CYP2C19'],{'CYP2C19': 'No Result'},{'CYP2C19': 'No Result'},{},{'CYP2C19': 'No Result'},RxNorm:121243,['CYP2C19 genotype may be important for voriconazole dosing and use. A CYP2C19 genotype does not appear to have been ordered for this patient. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171347,adults,Post-test,['CYP2C19'],{'CYP2C19': 'Ultrarapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Ultrarapid Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 ultrarapid metabolizer, and the probability of attainment of therapeutic concentrations is small. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as isavuconazole, liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Please consult a clinical pharmacist for more information.']",1
4171348,adults,Post-test,['CYP2C19'],{'CYP2C19': 'Rapid Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Rapid Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 rapid metabolizer, and the probability of attainment of therapeutic concentrations is modest. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as isavuconazole, liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Please consult a clinical pharmacist for more information.']",1
4171349,adults,No CDS,['CYP2C19'],{'CYP2C19': 'Normal Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Normal Metabolizer'},RxNorm:121243,['n/a'],1
4171350,adults,No CDS,['CYP2C19'],{'CYP2C19': 'Likely Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Intermediate Metabolizer'},RxNorm:121243,['n/a'],1
4171351,adults,No CDS,['CYP2C19'],{'CYP2C19': 'Intermediate Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Intermediate Metabolizer'},RxNorm:121243,['n/a'],1
4171352,adults,Post-test,['CYP2C19'],{'CYP2C19': 'Likely Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Likely Poor Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a likely CYP2C19 poor metabolizer, and higher than normal trough concentrations of voriconazole are likely and may increase the probability of adverse reactions. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as isavuconazole, liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Where voriconazole is strongly indicated for treatment of an invasive mycosis, administration of a lower dosage with meticulous therapeutic drug monitoring may be feasible. Please consult a clinical pharmacist for more information.']",1
4171353,adults,Post-test,['CYP2C19'],{'CYP2C19': 'Poor Metabolizer'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Poor Metabolizer'},RxNorm:121243,"['Based on the genotype result, this patient is predicted to be a CYP2C19 poor metabolizer, and higher than normal trough concentrations of voriconazole are likely and may increase the probability of adverse reactions. Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy instead of voriconazole such as isavuconazole, liposomal amphotericin B or posaconazole. Selection of an alternative agent should be based upon other clinical factors such as drug interactions, hepatic and/or renal function, suspected or documented fungal species, site of infection, and comorbidities. Where voriconazole is strongly indicated for treatment of an invasive mycosis, administration of a lower dosage with meticulous therapeutic drug monitoring may be feasible. Please consult a clinical pharmacist for more information.']",1
4171354,adults,No CDS,['CYP2C19'],{'CYP2C19': 'Indeterminate'},{'CYP2C19': 'n/a'},{},{'CYP2C19': 'Indeterminate'},RxNorm:121243,['n/a'],1
4171355,general,Pre-test,['HLA-B'],{},{},{'HLA-B': 'No *57:01 result on file'},{'HLA-B': 'No *57:01 result on file'},RxNorm:190521,"[""A HLA-B*57:01 genotype test is recommended before prescribing abacavir per the FDA's black box warning regarding the risk of serious hypersensitivity reactions in patients that carry this allele. A HLA-B*57:01 genotype test does not appear to have been ordered for this patient. Please do the following to order the HLA-B*57:01 genotype test (insert dialogue boxes here to order clinical HLA-B test).""]",1
4171356,general,No CDS,['HLA-B'],{},{},{'HLA-B': '*57:01 negative'},{'HLA-B': '*57:01 negative'},RxNorm:190521,['n/a'],1
4171357,general,Post-test,['HLA-B'],{},{},{'HLA-B': '*57:01 positive'},{'HLA-B': '*57:01 positive'},RxNorm:190521,"[""The HLA-B*57:01 allele has been detected in this patient. This allele is associated with high risk of severe hypersensitivity to abacavir. DO NOT prescribe abacavir per the FDA's black box warning. Please choose an alternate antiretroviral. For more information, please consult a clinical pharmacist.""]",1
4171378,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171379,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171380,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171381,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171382,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171383,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171384,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171385,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171386,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171387,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171388,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171389,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171390,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171391,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171392,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171393,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171394,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Please consult a clinical pharmacist for more information.']",1
4171395,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a atomoxetine-related adverse events. Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171396,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a atomoxetine-related adverse events. Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171397,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of a atomoxetine-related adverse events. Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171398,pediatrics,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of a atomoxetine-related adverse events. Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171399,pediatrics,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:38400,['n/a'],1
4171400,adults,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:38400,['CYP2D6 genetic status may be predictive of poor response to this medication. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171401,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171402,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171403,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171404,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171405,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171406,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171446,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. However, NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171407,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171408,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171409,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171410,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171411,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and it is unlikely this patient would achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171412,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171413,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171414,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171491,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171415,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:38400,"['Although this patient is predicted to be a CYP2D6 normal metabolizer, this patient may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171416,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 Intermediate metabolizer and may not achieve adequate serum concentrations for the intended effect at standard dosing. Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations. Please consult a clinical pharmacist for more information.']",1
4171417,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of atomoxetine-related adverse events. Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171418,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of atomoxetine-related adverse events. Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171419,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 intermediate metabolizer and may be at an increased risk of atomoxetine-related adverse events. Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171420,adults,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:38400,"['This patient is predicted to be a CYP2D6 poor metabolizer and may be at an increased risk of atomoxetine-related adverse events. Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose. Please consult a clinical pharmacist for more information.']",1
4171421,adults,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:38400,['n/a'],1
4171422,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171423,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. NUDT15 genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.""]",1
4171447,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171424,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171425,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.""]",1
4171426,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171427,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171428,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. TPMT genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions.NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171429,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'No Result'}","{'TPMT': 'No Result', 'NUDT15': 'No Result'}",{},"{'TPMT': 'No Result', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. Neither a TPMT or NUDT15 genotype appears to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171430,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171431,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171432,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171433,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171434,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171435,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171436,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171437,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 normal metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171571,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:5489,['n/a'],1
4171438,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible TPMT intermediate metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171439,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171440,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171441,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171442,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171443,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 normal metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171444,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT intermediate metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171445,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171448,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171449,general,No CDS,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,['n/a'],1
4171450,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171451,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of azathioprine. Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171452,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171453,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171454,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171455,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 normal metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171572,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:5489,['n/a'],1
4171456,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171457,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:1256,"[""Azathioprine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and possible NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of azathioprine and should receive greatly reduced doses. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. Please consult a clinical pharmacist for more information.""]",1
4171458,general,Pre-test,['DPYD'],{'DPYD': 'No Result'},{'DPYD': 'No Result'},{},{'DPYD': 'No Result'},RxNorm:194000,['DPYD genotype may be useful for capecitabine dosing and use. A DPYD genotype does not appear to have been ordered for this patient. Use of an alternative dose or agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171459,general,No CDS,['DPYD'],{'DPYD': 'Normal Metabolizer'},{'DPYD': '2.0'},{},{'DPYD': '2.0'},RxNorm:194000,['n/a'],1
4171460,general,Post-test,['DPYD'],{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.5'},{},{'DPYD': '1.5'},RxNorm:194000,"['Based on the genotype result, this patient is predicted to be a DPYD intermediate metabolizer (activity score 1.5) and has an increased risk of severe toxicity when treated with capecitabine. Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). To maintain efficacy, increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities. Please consult a clinical pharmacist for more information.']",1
4171461,general,Post-test,['DPYD'],{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.0'},{},{'DPYD': '1.0'},RxNorm:194000,"['Based on the genotype result, this patient is predicted to be a DPYD intermediate metabolizer (activity score 1) and has an increased risk of severe toxicity when treated with capecitabine. Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). To maintain efficacy, increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities. Please consult a clinical pharmacist for more information.']",1
4171462,general,Post-test,['DPYD'],{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.5'},{},{'DPYD': '0.5'},RxNorm:194000,"['Based on the genotype result, this patient is predicted to be a DPYD poor metabolizer (activity score 0.5) and has an increased risk of severe toxicity when treated with capecitabine. Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens in this patient. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring in order to immediately discontinue therapy if the drug level is too high. If available, a phenotyping test should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on capecitabine clearance. Please consult a clinical pharmacist for more information.']",1
4171463,general,Post-test,['DPYD'],{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.0'},{},{'DPYD': '0.0'},RxNorm:194000,"['Based on the genotype result, this patient is predicted to be a DPYD poor metabolizer (activity score 0) and has an increased risk of severe toxicity when treated with capecitabine. Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens in this patient. Please consult a clinical pharmacist for more information.']",1
4171464,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:140587,['CYP2C9 genotype may be important for celecoxib dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171465,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:140587,['n/a'],1
4171466,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:140587,['n/a'],1
4171467,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:140587,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of celecoxib which may increase the risk of toxicities. Initiate therapy with lowest recommended starting dose. Titrate dose to clinical effect or maximum recommended dose with caution. \nIn accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Please consult a clinical pharmacist for more information.']",1
4171573,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:5489,['n/a'],1
4171468,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:140587,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of celecoxib which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 8 days for celecoxib). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171469,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:140587,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of celecoxib which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 8 days for celecoxib). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171470,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:140587,['n/a'],1
4171471,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:2348,['n/a'],1
4171472,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:2348,['n/a'],1
4171473,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:2348,['n/a'],1
4171474,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:2348,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171475,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:2348,['n/a'],1
4171476,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:2348,['n/a'],1
4171477,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:2393,['n/a'],1
4171478,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:2393,['n/a'],1
4171479,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:2393,['n/a'],1
4171480,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:2393,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171481,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:2393,['n/a'],1
4171482,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:2393,['n/a'],1
4171483,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:2551,['n/a'],1
4171484,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:2551,['n/a'],1
4171485,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:2551,['n/a'],1
4171486,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:2551,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171487,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:2551,['n/a'],1
4171488,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:2551,['n/a'],1
4171489,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:2670,['CYP2D6 genotype is important for codeine and tramadol dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative analgesic agent (other than tramadol) may be recommended. Please consult a clinical pharmacist for more information.'],1
4171490,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171492,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171493,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171494,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171495,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171496,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171497,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171498,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171499,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171500,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171501,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:2670,['n/a'],1
4171502,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:2670,['n/a'],1
4171503,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:2670,['n/a'],1
4171504,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:2670,['n/a'],1
4171505,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:2670,['n/a'],1
4171506,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171507,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171508,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171574,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:5489,['n/a'],1
4171509,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171510,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:2670,"['This patient is predicted to be a CYP2D6 poor metabolizer and is at risk of having no analgesic response to codeine and tramadol. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171511,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:2670,['n/a'],1
4171512,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:3108,['G6PD status may be predictive of hemolytic anemia with dapsone. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent is recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171513,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:3108,['n/a'],1
4171514,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:3108,"['This patient has a result consistent with G6PD deficiency. Dapsone is very likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided. Stronlgy consider use of an alternative agent. If it is deemed that this medication remains the preferred agent, monitor the patient very closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171515,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:3108,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Dapsone is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171516,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:3108,['You are attempting to place an order for dapsone on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and dapsone is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171517,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:3108,['You are attempting to place an order for dapsone on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and dapsone is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171518,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:3328,['n/a'],1
4171519,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{},{},{'MT-RNR1': 'No Result'},RxNorm:3328,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171520,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:3328,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171521,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:3328,['n/a'],1
4171522,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:3445,['n/a'],1
4171523,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:3445,['n/a'],1
4171524,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:3445,['n/a'],1
4171525,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:3445,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171526,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:3445,['n/a'],1
4171527,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:3445,['n/a'],1
4171528,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:3639,['n/a'],1
4171529,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:3639,['n/a'],1
4171530,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:3639,['n/a'],1
4171531,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:3639,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171532,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:3639,['n/a'],1
4171533,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:3639,['n/a'],1
4171534,general,Pre-test,['DPYD'],{'DPYD': 'No Result'},{'DPYD': 'No Result'},{},{'DPYD': 'No Result'},RxNorm:4492,['DPYD genotype may be useful for 5-fluorouracil dosing and use. A DPYD genotype does not appear to have been ordered for this patient. Use of an alternative dose or agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171535,general,No CDS,['DPYD'],{'DPYD': 'Normal Metabolizer'},{'DPYD': '2.0'},{},{'DPYD': '2.0'},RxNorm:4492,['n/a'],1
4171536,general,Post-test,['DPYD'],{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.5'},{},{'DPYD': '1.5'},RxNorm:4492,"['Based on the genotype result, this patient is predicted to be a DPYD intermediate metabolizer (activity score 1.5) and has an increased risk of severe toxicity when treated with 5-fluorouracil. Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). To maintain efficacy, increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities. Please consult a clinical pharmacist for more information.']",1
4171537,general,Post-test,['DPYD'],{'DPYD': 'Intermediate Metabolizer'},{'DPYD': '1.0'},{},{'DPYD': '1.0'},RxNorm:4492,"['Based on the genotype result, this patient is predicted to be a DPYD intermediate metabolizer (activity score 1) and has an increased risk of severe toxicity when treated with 5-fluorouracil. Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). To maintain efficacy, increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities. Please consult a clinical pharmacist for more information.']",1
4171538,general,Post-test,['DPYD'],{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.5'},{},{'DPYD': '0.5'},RxNorm:4492,"['Based on the genotype result, this patient is predicted to be a DPYD poor metabolizer (activity score 0.5) and has an increased risk of severe toxicity when treated with 5-fluorouracil. Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens in this patient. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring in order to immediately discontinue therapy if the drug level is too high. If available, a phenotyping test should be considered to estimate the starting dose. In absence of phenotyping data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-fluorouracil clearance. Please consult a clinical pharmacist for more information.']",1
4171539,general,Post-test,['DPYD'],{'DPYD': 'Poor Metabolizer'},{'DPYD': '0.0'},{},{'DPYD': '0.0'},RxNorm:4492,"['Based on the genotype result, this patient is predicted to be a DPYD poor metabolizer (activity score 0) and has an increased risk of severe toxicity when treated with 5-fluorouracil. Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens in this patient. Please consult a clinical pharmacist for more information.']",1
4171540,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:4502,['CYP2C9 genotype may be important for flurbiprofen dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171541,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:4502,['n/a'],1
4171542,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:4502,['n/a'],1
4171543,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:4502,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of flurbiprofen which may increase the risk of toxicities. Initiate therapy with lowest recommended starting dose. Titrate dose to clinical effect or maximum recommended dose with caution. \nIn accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Please consult a clinical pharmacist for more information.']",1
4171544,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:4502,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of flurbiprofen which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for flurbiprofen). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171575,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:5489,['n/a'],1
4171545,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:4502,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of flurbiprofen which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for flurbiprofen). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171546,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:4502,['n/a'],1
4171547,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:4601,['n/a'],1
4171548,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:4601,['n/a'],1
4171549,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:4601,['n/a'],1
4171550,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:4601,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171551,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:4601,['n/a'],1
4171552,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:4601,['n/a'],1
4171553,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},ATC:D06AX07,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171554,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},ATC:D06AX07,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171555,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},ATC:D06AX07,['n/a'],1
4171556,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},ATC:D06AX07,['n/a'],1
4171557,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:4815,['n/a'],1
4171558,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:4815,['n/a'],1
4171559,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:4815,['n/a'],1
4171560,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:4815,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171561,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:4815,['n/a'],1
4171562,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:4815,['n/a'],1
4171563,Hydrocodone,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:5489,['CYP2D6 genotype may be important for hydrocodone dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative analgesic agent (other than codeine and tramadol) may be recommended. Please consult a clinical pharmacist for more information.'],1
4171564,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:5489,['n/a'],1
4171565,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:5489,['n/a'],1
4171566,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:5489,['n/a'],1
4171567,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:5489,['n/a'],1
4171568,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:5489,['n/a'],1
4171569,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:5489,['n/a'],1
4171570,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:5489,['n/a'],1
4171580,Hydrocodone,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:5489,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to hydrocodone, codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171581,Hydrocodone,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:5489,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to hydrocodone, codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171582,Hydrocodone,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:5489,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to hydrocodone, codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171583,Hydrocodone,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:5489,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171584,Hydrocodone,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:5489,"['This patient is predicted to be a CYP2D6 poor metabolizer possibly resulting in decreased analgesia to hydrocodone, codeine and tramadol. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid codeine and tramadol. Please consult a clinical pharmacist for more information.']",1
4171585,Hydrocodone,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:5489,['n/a'],1
4171586,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:5521,['n/a'],1
4171587,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:5521,['n/a'],1
4171588,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:5521,['n/a'],1
4171589,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:5521,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171590,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:5521,['n/a'],1
4171591,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:5521,['n/a'],1
4171592,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:5640,['CYP2C9 genotype may be important for ibuprofen dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171593,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:5640,['n/a'],1
4171594,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:5640,['n/a'],1
4171595,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:5640,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of ibuprofen which may increase the risk of toxicities. Initiate therapy with lowest recommended starting dose. Titrate dose to clinical effect or maximum recommended dose with caution. \nIn accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Please consult a clinical pharmacist for more information.']",1
4171596,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:5640,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of ibuprofen which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for ibuprofen). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171597,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:5640,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of ibuprofen which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for ibuprofen). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171598,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:5640,['n/a'],1
4171599,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:6099,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171600,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:6099,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171601,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:6099,['n/a'],1
4171602,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:6099,['n/a'],1
4171603,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:20890,['CYP2C9 genotype may be important for lornoxicam dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171604,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:20890,['n/a'],1
4171605,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:20890,['n/a'],1
4171606,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:20890,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of lornoxicam which may increase the risk of toxicities. Initiate therapy with lowest recommended starting dose. Titrate dose to clinical effect or maximum recommended dose with caution. \nIn accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Please consult a clinical pharmacist for more information.']",1
4171607,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:20890,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of lornoxicam which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for lornoxicam). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171608,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:20890,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of lornoxicam which may increase the risk of toxicities. Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 5 days for lornoxicam). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo. Please consult a clinical pharmacist for more information.']",1
4171609,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:20890,['n/a'],1
4171610,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:6572,['n/a'],1
4171611,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:6572,['n/a'],1
4171612,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:6572,['n/a'],1
4171613,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:6572,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171614,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:6572,['n/a'],1
4171615,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:6572,['n/a'],1
4171616,general,Pre-test,['CYP2C9'],{'CYP2C9': 'No Result'},{'CYP2C9': 'No Result'},{},{'CYP2C9': 'No Result'},RxNorm:41493,['CYP2C9 genotype may be important for meloxicam dosing and use. A CYP2C9 genotype does not appear to have been ordered for this patient. Use of an alternative agent or dose may be recommended. Please consult a clinical pharmacist for more information.'],1
4171617,general,No CDS,['CYP2C9'],{'CYP2C9': 'Normal Metabolizer'},{'CYP2C9': '2.0'},{},{'CYP2C9': '2.0'},RxNorm:41493,['n/a'],1
4171618,general,No CDS,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.5'},{},{'CYP2C9': '1.5'},RxNorm:41493,['n/a'],1
4171619,general,Post-test,['CYP2C9'],{'CYP2C9': 'Intermediate Metabolizer'},{'CYP2C9': '1.0'},{},{'CYP2C9': '1.0'},RxNorm:41493,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Intermediate Metabolizer with an activity score of 1 and is expected to have higher plasma concentrations of meloxicam which may increase the risk of toxicities. Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, celecoxib, fluriprofen, lornoxicam, and ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171620,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.5'},{},{'CYP2C9': '0.5'},RxNorm:41493,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0.5 and is expected to have higher plasma concentrations of meloxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171621,general,Post-test,['CYP2C9'],{'CYP2C9': 'Poor Metabolizer'},{'CYP2C9': '0.0'},{},{'CYP2C9': '0.0'},RxNorm:41493,"['Based on the genotype result, this patient is predicted to be a CYP2C9 Poor Metabolizer with an activity score of 0 and is expected to have higher plasma concentrations of meloxicam which may increase the risk of toxicities. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (such as celecoxib, flurbiprofen, lornoxicam, or ibuprofen). Please consult a clinical pharmacist for more information.']",1
4171622,general,No CDS,['CYP2C9'],{'CYP2C9': 'Indeterminate'},{'CYP2C9': 'n/a'},{},{'CYP2C9': 'n/a'},RxNorm:41493,['n/a'],1
4171623,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171624,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. NUDT15 genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171636,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171625,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171626,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,"['This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.']",1
4171627,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. Initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171628,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5mg/kg/day, dose reduction may not be recommended. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171629,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. TPMT genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171630,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'No Result'}","{'TPMT': 'No Result', 'NUDT15': 'No Result'}",{},"{'TPMT': 'No Result', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. Neither a TPMT or NUDT15 genotype appears to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171682,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:7454,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Nitrofurantoin may cause hemolytic anemia and worsen any existing anemia and should be avoided. Consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171631,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171632,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171633,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. Initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171634,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171635,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171651,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171637,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171638,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 normal metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already <75mg/m2/day or < 1.5mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171639,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible TPMT poor metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171640,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171641,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171642,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171677,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:7337,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171643,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171644,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 normal metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already <75mg/m2/day or < 1.5mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171645,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT intermediate metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171646,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171647,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. However, NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171648,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171649,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171650,general,No CDS,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,['n/a'],1
4171678,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:7337,['n/a'],1
4171652,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of 6-mercaptopurine. Consider starting 6-mercaptopurine at 30-80% of normal dose if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. Please consult a clinical pharmacist for more information.""]",1
4171653,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171654,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171655,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171656,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 normal metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171657,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week, (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171679,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:7454,['G6PD status may be predictive of hemolytic anemia with nitrofurantoin. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Increased monitoring for signs of hemolysis may be recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171680,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:7454,['n/a'],1
4171658,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:103,"[""6-mercaptopurine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and possible NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of 6-mercaptopurine and should receive greatly reduced doses. For malignancy, start with reducing the normal single dose for 6-mercaptopurine by 90% and administer three times a week (e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171659,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:6878,['G6PD status may be predictive of hemolytic anemia with methylene blue. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent may be recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171660,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:6878,['n/a'],1
4171661,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:6878,"['This patient has a result consistent with G6PD deficiency. Methylene blue is very likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided. Strongly consider use of an alternative agent. If it is deemed that this medication remains the preferred agent, monitor the patient closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171662,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:6878,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Methylene blue is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171663,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:6878,['You are attempting to place an order for methylene blue on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and methylene blue is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171664,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:6878,['You are attempting to place an order for methylene blue on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and methylene blue is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171665,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:7240,['n/a'],1
4171666,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:7240,['n/a'],1
4171667,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:7240,['n/a'],1
4171668,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:7240,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171669,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:7240,['n/a'],1
4171670,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:7240,['n/a'],1
4171671,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:7299,['n/a'],1
4171672,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{},{},{'MT-RNR1': 'No Result'},RxNorm:7299,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171673,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:7299,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171674,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:7299,['n/a'],1
4171675,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:7337,['n/a'],1
4171676,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{},{},{'MT-RNR1': 'No Result'},RxNorm:7337,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171683,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:7454,['You are attempting to place an order for nitrofurantoin on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and nitrofurantoin is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171684,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:7454,['You are attempting to place an order for nitrofurantoin on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and nitrofurantoin is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171685,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:7517,['n/a'],1
4171686,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:7517,['n/a'],1
4171687,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:7517,['n/a'],1
4171688,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:7517,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171689,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:7517,['n/a'],1
4171690,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:7517,['n/a'],1
4171691,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:7623,['n/a'],1
4171692,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:7623,['n/a'],1
4171693,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:7623,['n/a'],1
4171694,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:7623,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171695,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:7623,['n/a'],1
4171696,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:7623,['n/a'],1
4171697,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:7934,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171698,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:7934,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171699,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:7934,['n/a'],1
4171700,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:7934,['n/a'],1
4171701,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:1011650,['G6PD status may be predictive of hemolytic anemia with pegloticase. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent is recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171702,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:1011650,['n/a'],1
4171703,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:1011650,"['This patient has a result consistent with G6PD deficiency. Pegloticase is very likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided. Strongly consider use of an alternative agent. If it is deemed that this medication remains the preferred agent, monitor the patient closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171704,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:1011650,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Pegloticase is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Stronlgy consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171725,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:9071,['n/a'],1
4171705,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:1011650,['You are attempting to place an order for pegloticase on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and pegloticase is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171706,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:1011650,['You are attempting to place an order for pegloticase on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and pegloticase is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171707,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:8120,['n/a'],1
4171708,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:8120,['n/a'],1
4171709,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:8120,['n/a'],1
4171710,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:8120,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171711,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:8120,['n/a'],1
4171712,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:8120,['n/a'],1
4171713,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:2049549,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171714,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:2049549,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171715,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:2049549,['n/a'],1
4171716,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:2049549,['n/a'],1
4171717,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:8687,"['G6PD status may be predictive of hemolytic anemia with primaquine, depending on the primaquine dosage regimen. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Increased monitoring for signs of hemolysis or alternative agent may be recommended if the patient is G6PD deficient, depending on dosage. Please consult a clinical pharmacist for more information.']",1
4171718,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:8687,['n/a'],1
4171719,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:8687,"['This patient has a result consistent with G6PD deficiency. Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium falciparum malaria by using primaquine as a gametocytocide: 0.25 mg/kg x1 dose (WHO)--without need for monitoring for hemolysis; and (2) treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC)---with close monitoring for hemolysis. Please consult a clinical pharmacist for more information.']",1
4171720,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:8687,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Primaquine is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171721,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:8687,"['You are attempting to place an order for primaquine on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and primaquine is prescribed, depending on the dose. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.']",1
4171722,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:8687,['You are attempting to place an order for primaquine on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and primaquine is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171723,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:9071,['n/a'],1
4171724,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:9071,['n/a'],1
4171726,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:9071,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171727,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:9071,['n/a'],1
4171728,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:9071,['n/a'],1
4171729,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:283821,['G6PD status may be predictive of hemolytic anemia with rasburicase. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent is recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171730,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:283821,['n/a'],1
4171731,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:283821,"['This patient has a result consistent with G6PD deficiency. Rasburicase is very likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided. Strongly consider use of an alternative agent. If it is deemed that this medication remains the preferred agent, monitor the patient closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171732,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:283821,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Rasburicase is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171733,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:283821,['You are attempting to place an order for rasburicase on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and rasburicase is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171734,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:283821,['You are attempting to place an order for rasburicase on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient and rasburicase is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171735,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:NA,['n/a'],1
4171736,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{},{},{'MT-RNR1': 'No Result'},RxNorm:NA,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171737,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:NA,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171738,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:NA,['n/a'],1
4171739,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:10109,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171740,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:10109,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171741,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:10109,['n/a'],1
4171742,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:10109,['n/a'],1
4171743,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10171,['n/a'],1
4171744,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10171,['n/a'],1
4171745,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10171,['n/a'],1
4171778,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10207,['n/a'],1
4171746,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10171,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171747,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10171,['n/a'],1
4171748,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10171,['n/a'],1
4171749,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10178,['n/a'],1
4171750,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10178,['n/a'],1
4171751,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10178,['n/a'],1
4171752,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10178,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171753,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10178,['n/a'],1
4171754,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10178,['n/a'],1
4171755,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10831,['n/a'],1
4171756,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10831,['n/a'],1
4171757,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10831,['n/a'],1
4171758,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10831,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171759,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10831,['n/a'],1
4171760,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10831,['n/a'],1
4171761,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10184,['n/a'],1
4171762,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10184,['n/a'],1
4171763,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10184,['n/a'],1
4171764,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10184,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171765,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10184,['n/a'],1
4171766,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10184,['n/a'],1
4171767,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:9524,['n/a'],1
4171768,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:9524,['n/a'],1
4171769,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:9524,['n/a'],1
4171770,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:9524,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171771,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:9524,['n/a'],1
4171772,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:9524,['n/a'],1
4171773,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10207,['n/a'],1
4171774,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10207,['n/a'],1
4171775,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10207,['n/a'],1
4171776,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10207,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171777,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10207,['n/a'],1
4171779,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:2054023,['G6PD status is predictive of hemolytic anemia with tafenoquine. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent may be recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171780,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:2054023,['n/a'],1
4171781,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:2054023,"['This patient has a result consistent with G6PD deficiency. Tafenoquine is likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided; tafenoquine safety was demonstrated only in those with G6PD activity ≥70% of normal. Strongly consider use of an alternative agent. If it is deemed that this medication remains the preferred agent, monitor the patient very closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171782,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:2054023,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Tafenoquine is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171783,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:2054023,"['You are attempting to place an order for tafenoquine on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient or if G6PD activity is less than 70% of normal and tafenoquine is prescribed; in such cases, alternatives to tafenoquine should be strongly considered. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.']",1
4171784,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:2054023,"['You are attempting to place an order for tafenoquine on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient is at increased risk of developing hemolytic anemia if they are G6PD deficient or if G6PD activity is less than 70% of normal and tafenoquine is prescribed; in such cases, alternatives to tafenoquine should be strongly considered. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.']",1
4171785,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thioguanine is required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.""]",1
4171786,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. NUDT15 genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. Please consult a clinical pharmacist for more information.""]",1
4171787,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171788,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171834,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10638,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Toluidine blue is very likely to cause hemolytic anemia and worsen any existing anemia and should be avoided. Strongly consider use of an alternative agent. Please consult a clinical pharmacist for more information.'],1
4171789,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171790,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Indeterminate', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. However, TPMT phenotype could not be assigned based on genotyping performed. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171791,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. TPMT genotype does not appear to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171792,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'No Result'}","{'TPMT': 'No Result', 'NUDT15': 'No Result'}",{},"{'TPMT': 'No Result', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. Neither a TPMT or NUDT15 genotype appears to have been ordered for this patient. Based on those results, use of an alternative dose or drug may be recommended. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171793,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171794,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the NUDT15 result. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171808,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171795,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a NUDT15 poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171796,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'No Result', 'NUDT15': 'n/a'}",{},"{'TPMT': 'No Result', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible NUDT15 intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Because a TPMT genotype does not appear to have been ordered for this patient, it is not known if TPMT results would further influence the recommended dose or drug. If thiopurines are required and TPMT genotype status is unknown, consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. Erythrocyte TPMT activity test results can be falsely low at diagnosis of leukemia and is unreliable in the case of recent red blood cell transfusions. Please consult a clinical pharmacist for more information.""]",1
4171797,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. However, NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171798,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171799,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171800,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and NUDT15 normal metabolizer. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171809,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. However, NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171801,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a possible TPMT intermediate metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171802,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Possible Intermediate Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be possible TPMT intermediate metabolizer and possible NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171803,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. However, NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171804,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171805,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 intermediate metabolizer. This patient is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171806,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be TPMT intermediate metabolizer and NUDT15 normal metabolizer. This patient is at risk for myelosuppression with normal doses of thioguanine. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171807,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Intermediate Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT intermediate metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171851,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:10689,['n/a'],1
4171852,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:10689,['n/a'],1
4171810,general,Pre-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer; there is no reason to selectively adjust the dose of this medication based on the TPMT result. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171811,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 intermediate metabolizer. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171812,general,No CDS,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,['n/a'],1
4171813,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171814,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Normal Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT normal metabolizer and possible NUDT15 intermediate metabolizer. Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents. Please consult a clinical pharmacist for more information.""]",1
4171815,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Indeterminate'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. However, NUDT15 phenotype could not be assigned based on genotyping. Monitor closely for toxicity. Please consult a clinical pharmacist for more information.""]",1
4171816,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}","{'TPMT': 'n/a', 'NUDT15': 'No Result'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'No Result'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Because a NUDT15 genotype does not appear to have been ordered for this patient, it is not known if NUDT15 results would further influence the recommended dose or drug. Please consult a clinical pharmacist for more information.""]",1
4171817,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171853,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:10689,['n/a'],1
4171818,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Normal Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 normal metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171819,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Poor Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and NUDT15 poor metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171820,general,Post-test,"['TPMT', 'NUDT15']","{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}","{'TPMT': 'n/a', 'NUDT15': 'n/a'}",{},"{'TPMT': 'Poor Metabolizer', 'NUDT15': 'Possible Intermediate Metabolizer'}",RxNorm:10485,"[""Thioguanine can be affected by a patient's TPMT and NUDT15 phenotype. This patient is predicted to be a TPMT poor metabolizer and possible NUDT15 intermediate metabolizer. This patient is at high risk for life threatening myelosuppression with normal doses of thioguanine and should receive greatly reduced doses. Start with drastically reduced doses (reduce daily dose by 10 fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. Please consult a clinical pharmacist for more information.""]",1
4171821,general,Pre-test,['MT-RNR1'],{'MT-RNR1': 'No Result'},{'MT-RNR1': 'No Result'},{},{'MT-RNR1': 'No Result'},RxNorm:10627,['A MT-RNR1 genotype does not appear to have been ordered for this patient. MT-RNR1 genotype may be an important risk factor for aminoglycoside-induced hearing loss. Use of an alternative agent may be recommended. Please consult a clinical pharmacist for more information.'],1
4171822,general,Post-test,['MT-RNR1'],{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'increased risk of aminoglycoside-induced hearing loss'},RxNorm:10627,"['Based on the MT-RNR1 genotype result, this patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. Aminoglycosides are likely to cause IRREVERSIBLE hearing loss in this patient. For help with selecting an alternative agent, please consult a clinical pharmacist or Infectious Diseases Service.']",1
4171823,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'normal risk of aminoglycoside-induced hearing loss'},RxNorm:10627,['n/a'],1
4171824,general,No CDS,['MT-RNR1'],{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},{'MT-RNR1': 'n/a'},{},{'MT-RNR1': 'uncertain risk of aminoglycoside-induced hearing loss'},RxNorm:10627,['n/a'],1
4171825,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10635,['n/a'],1
4171826,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10635,['n/a'],1
4171827,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10635,['n/a'],1
4171828,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:10635,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171829,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10635,['n/a'],1
4171830,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10635,['n/a'],1
4171831,general,Pre-test,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:10638,['G6PD status may be predictive of hemolytic anemia with toluidine blue. A G6PD test does not appear to have been ordered for this patient. Consider ordering a G6PD genotype or enzyme activity test. Use of an alternative agent may be recommended if the patient is G6PD deficient. Please consult a clinical pharmacist for more information.'],1
4171832,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:10638,['n/a'],1
4171833,general,Post-test,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:10638,"['This patient has a result consistent with G6PD deficiency. Toluidine blue is very likely to cause hemolytic anemia in patients with G6PD deficiency and should be avoided. Strongly consider use of an alternative agent. If this medication is the preferred agent, monitor the patient closely for signs of hemolysis. Please consult a clinical pharmacist for more information.']",1
4171900,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:39786,['n/a'],1
4171835,general,Post-test,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:10638,['You are attempting to place an order for toluidine blue on a patient whose G6PD genotype results in a phenotype assignment of variable G6PD activity (enzyme activity could range from normal to deficient). The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and toluidine blue is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171836,general,Post-test,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:10638,['You are attempting to place an order for toluidine blue on a patient whose G6PD genotype does not allow an assignment of G6PD phenotype. The patient may be at increased risk of developing hemolytic anemia if they are G6PD deficient and toluidine blue is prescribed. A test of G6PD enzyme activity may be informative. Please consult a clinical pharmacist for more information.'],1
4171837,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:10689,['CYP2D6 genotype is important for tramadol and codeine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative analgesic agent (other than codeine) may be recommended. Please consult a clinical pharmacist for more information.'],1
4171838,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171839,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171840,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171841,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171842,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171843,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171844,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171845,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171846,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171847,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171848,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at increased risk of developing toxicities to tramadol and codeine. Consider selecting an alternative analgesic agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171849,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:10689,['n/a'],1
4171850,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:10689,['n/a'],1
4171854,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to tramadol and codeine. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid tramadole and codeine. Please consult a clinical pharmacist for more information.']",1
4171855,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to tramadol and codeine. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171856,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to tramadol and codeine Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171857,general,Post-test,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 intermediate metabolizer possibly resulting in decreased analgesia to tramadol and codeine. Initiate therapy at the recommended age and weight specific dosing. If no adequate analgesic response, consider selecting an alternative agent. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171858,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:10689,"['This patient is predicted to be a CYP2D6 poor metabolizer and is at risk of having no analgesic response. Consider selecting an alternative analgesic agent to tramadol and codeine. If opioid use is warranted, avoid tramadol and codeine. Please consult a clinical pharmacist for more information.']",1
4171859,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:10689,['n/a'],1
4171860,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:27392,['CYP2D6 genetic status may be predictive of poor response to this medication. A CYP2D6 genotype does not appear to have been ordered for this patient. Use of an alternative drug may be recommended. Please consult a clinical pharmacist for more information.'],1
4171861,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171862,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171863,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171864,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171865,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171866,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171867,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171868,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171869,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171870,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171871,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:27392,"['This patient is predicted to be a CYP2D6 ultrarapid metabolizer and may be at an increased risk of a poor response due to low plasma concentrations of tropisetron. Consider selecting an alternative medication not extensively metabolized by CYP2D6 (i.e., granisetron). Please consult a clinical pharmacist for more information.']",1
4171872,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:27392,['n/a'],1
4171873,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:27392,['n/a'],1
4171874,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:27392,['n/a'],1
4171875,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:27392,['n/a'],1
4171876,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:27392,['n/a'],1
4171877,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:27392,['n/a'],1
4171878,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:27392,['n/a'],1
4171879,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:27392,['n/a'],1
4171880,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:27392,['n/a'],1
4171881,general,No CDS,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:27392,['n/a'],1
4171882,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:27392,['n/a'],1
4171883,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:39786,['CYP2D6 genotype may be important for venlafaxine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171884,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:39786,['n/a'],1
4171885,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:39786,['n/a'],1
4171886,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:39786,['n/a'],1
4171887,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:39786,['n/a'],1
4171888,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:39786,['n/a'],1
4171889,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:39786,['n/a'],1
4171890,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:39786,['n/a'],1
4171891,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:39786,['n/a'],1
4171892,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:39786,['n/a'],1
4171893,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:39786,['n/a'],1
4171894,general,No CDS,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:39786,['n/a'],1
4171895,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:39786,['n/a'],1
4171896,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:39786,['n/a'],1
4171897,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:39786,['n/a'],1
4171898,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:39786,['n/a'],1
4171899,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:39786,['n/a'],1
4171904,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:39786,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4171905,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:39786,['n/a'],1
4171906,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:1151,['n/a'],1
4171907,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:1151,['n/a'],1
4171908,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:1151,['n/a'],1
4171909,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:1151,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171910,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:1151,['n/a'],1
4171911,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:1151,['n/a'],1
4171912,general,No CDS,['G6PD'],{'G6PD': 'No Result'},{},{},{'G6PD': 'No Result'},RxNorm:11258,['n/a'],1
4171913,general,No CDS,['G6PD'],{'G6PD': 'Normal'},{},{},{'G6PD': 'Normal'},RxNorm:11258,['n/a'],1
4171914,general,No CDS,['G6PD'],{'G6PD': 'Deficient'},{},{},{'G6PD': 'Deficient'},RxNorm:11258,['n/a'],1
4171915,general,Post-test,['G6PD'],{'G6PD': 'Deficient with CNSHA'},{},{},{'G6PD': 'Deficient with CNSHA'},RxNorm:11258,['This patient has a result consistent with G6PD deficiency with chronic nonspherocytic hemolytic anemia (CNSHA). Increased monitoring for worsening of hemolytic anemia may be indicated for patients with G6PD deficiency with CNSHA who receive medications. Please consult a clinical pharmacist for more information.'],1
4171916,general,No CDS,['G6PD'],{'G6PD': 'Variable'},{},{},{'G6PD': 'Variable'},RxNorm:11258,['n/a'],1
4171917,general,No CDS,['G6PD'],{'G6PD': 'Indeterminate'},{},{},{'G6PD': 'Indeterminate'},RxNorm:11258,['n/a'],1
4171918,general,Pre-test,['CYP2D6'],{'CYP2D6': 'No Result'},{'CYP2D6': 'No Result'},{},{'CYP2D6': 'No Result'},RxNorm:1455099,['CYP2D6 genotype may be important for vortioxetine dosing and use. A CYP2D6 genotype does not appear to have been ordered for this patient. Please consult a clinical pharmacist for more information.'],1
4171919,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥6.0'},{},{'CYP2D6': '≥6.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171920,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥5.0'},{},{'CYP2D6': '≥5.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171921,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥4.0'},{},{'CYP2D6': '≥4.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171922,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.75'},{},{'CYP2D6': '≥3.75'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171923,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.5'},{},{'CYP2D6': '≥3.5'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171924,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.25'},{},{'CYP2D6': '≥3.25'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171925,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '≥3.0'},{},{'CYP2D6': '≥3.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171926,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '4.0'},{},{'CYP2D6': '4.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171927,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '3.0'},{},{'CYP2D6': '3.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171928,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.75'},{},{'CYP2D6': '2.75'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171929,general,Post-test,['CYP2D6'],{'CYP2D6': 'Ultrarapid Metabolizer'},{'CYP2D6': '2.5'},{},{'CYP2D6': '2.5'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 ultrarapid metabolizer and is at risk for lower plasma concentrations and increased probability of therapeutic failure with standard dosing. Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy. Please consult a clinical pharmacist for more information.']",1
4171930,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.25'},{},{'CYP2D6': '2.25'},RxNorm:1455099,['n/a'],1
4171931,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '2.0'},{},{'CYP2D6': '2.0'},RxNorm:1455099,['n/a'],1
4171932,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.75'},{},{'CYP2D6': '1.75'},RxNorm:1455099,['n/a'],1
4171933,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.5'},{},{'CYP2D6': '1.5'},RxNorm:1455099,['n/a'],1
4171934,general,No CDS,['CYP2D6'],{'CYP2D6': 'Normal Metabolizer'},{'CYP2D6': '1.25'},{},{'CYP2D6': '1.25'},RxNorm:1455099,['n/a'],1
4171935,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '1.0'},{},{'CYP2D6': '1.0'},RxNorm:1455099,['n/a'],1
4171936,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.75'},{},{'CYP2D6': '0.75'},RxNorm:1455099,['n/a'],1
4171937,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.5'},{},{'CYP2D6': '0.5'},RxNorm:1455099,['n/a'],1
4171938,general,No CDS,['CYP2D6'],{'CYP2D6': 'Intermediate Metabolizer'},{'CYP2D6': '0.25'},{},{'CYP2D6': '0.25'},RxNorm:1455099,['n/a'],1
4171939,general,Post-test,['CYP2D6'],{'CYP2D6': 'Poor Metabolizer'},{'CYP2D6': '0.0'},{},{'CYP2D6': '0.0'},RxNorm:1455099,"['Based on the genotype result, this patient is predicted to be a CYP2D6 poor metabolizer and is at risk for higer plasma concentrations and increased probability of side effects with standard dosing. Initiate 50% of starting dose (e.g., 5 mg) and titrate to the maximum recommended dose of 10 mg or consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6. Please consult a clinical pharmacist for more information.']",1
4171940,general,No CDS,['CYP2D6'],{'CYP2D6': 'Indeterminate'},{'CYP2D6': 'n/a'},{},{'CYP2D6': 'n/a'},RxNorm:1455099,['n/a'],1
